

# 1 Introduction

2 Cancer biology features the ascription of normal functions to parts of cancers. At  
3 least some ascriptions of function in cancer biology track local normality of parts  
4 within the global abnormality of the aberration to which those parts belong. That is,  
5 cancer biologists identify as functions activities that, in some sense, parts of cancers  
6 are *supposed* to perform, despite cancers themselves having no purpose. The present  
7 paper provides a theory to accommodate these normal function ascriptions—I call it  
8 the Modeling Account of Normal Function (MA). MA comprises two claims. First,  
9 that normal functions are activities whose performance by the function-bearing part  
10 contributes to the self-maintenance of the whole system and, thereby, results in the  
11 continued presence of that part. Second, MA holds that there is a class of models  
12 of system-level activities (partly) constitutive of self-maintenance members of which  
13 are improved by including a representation of the relevant function-bearing part and  
14 by making reference to the activity or activities that part performs and which con-  
15 tribute(s) to those system-level activities. Following Godfrey-Smith (2006, 2009b)  
16 and Levy (2015), I take models to be representations that abstract and idealize fea-  
17 tures of what they represent—their targets—with a view to predicting or explaining  
18 the behavior of those targets. A consequence of MA is that normal functions are pri-  
19 marily an explanatory kind, ascribed by biologists with a view to getting a grip on  
20 standard part-level causes of system-level phenomena of interest and, in the case of  
21 cancer biology at least, devising effective clinical interventions. That is, in the case of  
22 cancer biology, the point of identifying standards of activity among a type of trait and  
23 within a type of cancer is to devise ways of undermining that activity to slow or stop  
24 disease progression. The claim that normal functions are explanatory kinds places  
25 MA within a pragmatist tradition in the philosophy of biology that is concerned with  
26 function (Hardcastle, 2002; Laubichler et al, 2015; Keeling et al, 2019). I contrast  
27 MA with two other, more purely metaphysical accounts that seek to explicate the  
28 ascription of normal functions in biology, namely, the organizational account and the  
29 selected effects account. It turns out that both struggle to extend to cancer biology.  
30 However, I offer ecumenical readings of modified forms of each which allow them to  
31 recover some ascriptions of normal function to parts of cancers. So, although I con-  
32 tend that MA excels in this respect, the purpose of this paper is served if it provides  
33 materials for bridging the gap between cancer biology, the philosophy of cancer, and  
34 the literature on function.

35 In §2, I briefly discuss function pluralism and introduce two desiderata on what  
36 are sometimes called “descriptive” accounts of function. §3 presents a representative  
37 example of cancer biologists ascribing a normal function to a part of a type of cancer.  
38 §4 introduces MA and applies it to the example presented in §3. §5 contrasts the  
39 success of MA in satisfying both desiderata relative to normal function ascription in  
40 cancer biology with the other two accounts. I consider two objections to the claim that  
41 cancer biologists ascribe normal functions to parts of cancers in §6 before concluding  
42 with a comment on the philosophy of biology in §7.

## 2 Desiderata on Descriptive Accounts of Function and Normal Function

### 2.1 Function and Pluralism

In this section, I briefly discuss the state of the function literature in the philosophy of biology (for extensive overviews, see Wouters, 2005; Garson, 2016) and introduce two desiderata on any account of function that seeks to explicate its ascription in biology. Function ascription is pervasive in biology. Following Weber (2017, 4744–4746), who generalizes from Cummins (1975)’s causal role account (see also fn.7), functions are , to a first approximation, activities<sup>1</sup> that parts<sup>2</sup> of biological systems perform and whose performance contributes in some way to those systems. To take the philosopher’s favorite example, the function of the heart is to pump blood. This ascription tells us, first, that hearts pump blood and, second, that pumping blood contributes in some way to biological systems with hearts, for instance, by helping transport nutrients and waste to and from various tissues in the body. Ascribing a function explains by drawing our attention to the dispositions and/or structural features of systems that are causally relevant for system-level phenomena of interest. Biologists are keen to understand how or why biological systems persist and propagate. Functions indicate how those systems do so or why they have those dispositions and/or structural features which, in the good case at least, allow them to do so.<sup>3</sup>

There are at least two concepts of function at work in biology. The first applies to activities that traits in fact perform(ed). Consider cladistic systematics, the branch of biology that studies common descent and changes in phenotype as a function of descent. When studying a phenotypic trait, systematists ascribe a function to it either to mark continuity in the activity performed by that trait with that of traits in ancestral systems or as evidence of innovation in that trait or its activity (Griffiths, 2006). For instance, a systematist might ascribe to the tail of *Crocodylus* the function of propelling the animal through its aquatic habitat in recognition of the fact that an ancestral genus, *Myriosuchus*, made the same adaptive use of its archosaur tail (Griffiths, 1994, 218–219). Or the systematist might ascribe to the carapace of *Proganochelys* (a genus of proto-turtle) the function of protection in recognition of its novelty as a trait. In this case, functions are activities that traits perform(ed). Their ascription does not necessarily tell us what a trait should be doing, only what it does or did or its past or present causal role (Cummins, 1975; Amundson and Lauder, 1994; cf. Neander, 2002; Garson, 2016, 7, 50–51, 90–91).

The second function concept at work in biology is often discussed under the heading of “normal function.” Normal functions are activities that traits are *supposed* to perform. Consider physiology, the branch of biology which is said to study the normal functions of parts of organisms (Roux, 2014). When physiologists say of the heart that its function is to pump blood, they do so in full awareness that not all hearts

<sup>1</sup>I use “activity” for both processes and continuous states, e.g., presence of the ventricular septum.

<sup>2</sup>I use “part” and “trait” interchangeably to cover system-level and subsystem traits, parts, components, phenotypes, characters, items, and genotypes except in contexts where using one of the other terms provides greater clarity.

<sup>3</sup>On the distinction between How-questions and Why-questions in biology and their relationship to functional analysis, see Mayr (1961); cf. Neander (2017b, especially Chapter 3)

1 pump blood. In this case, the functions referred to as normal are normative in the min-  
2 imal sense that they *embody a standard for trait-activity* (Roux, 2014, 2248; Garson,  
3 2016, 5-6, 36, 48). Ascribing a normal function tells us not what a token trait actually  
4 does but what that trait, *as a token of a particular type*, is supposed to do and, *thereby*,  
5 what it is supposed to be disposed to do and/or the structure it is supposed to have  
6 so that it can perform its function.<sup>4</sup> Identifying a standard for trait-activity and, thus,  
7 disposition and/or structure guides identification of instances of that trait *as being of*  
8 *the same type* despite variation between individuals, system types, and environments.  
9 A heart that cannot pump, is not disposed to pump, or fails to have the structure that  
10 allows it to pump is still recognizable as an instance of the type at least in part by  
11 appeal to its normal function. Ditto for morphologically distinct hearts across species  
12 and environments.

13 I do not take these two to exhaust the set of function concepts that are applied in  
14 biology. However, they are sufficient to point to a lack of uniformity in the application  
15 of a single function concept across the discipline. This lack of uniformity has driven  
16 several philosophers writing on the subject to adopt function pluralism (for instance,  
17 Godfrey-Smith, 1993; Amundson and Lauder, 1994; Allen and Bekoff, 1995; Mil-  
18 likan, 1999, 2002; Arp, 2007; Bouchard, 2013; Brandon, 2013; Neander, 2017a,b;  
19 Garson, 2018; *cf.* Kitcher, 1993; Steiner, 2009; Nanay, 2010; van Hateren, 2017).  
20 Function pluralism is the view that no one account of function unifies application of  
21 the concept across biology. An effect of adopting pluralism is that disputes in the lit-  
22 erature become territorial, characterized by arguments that some account explicates  
23 or fails to explicate the ascription of function within this or that (part of a) subdis-  
24 cipline of biology (for an example of such a dispute, see Griffiths, 1994; Amundson  
25 and Lauder, 1994; Neander, 2002; Rosenberg and Neander, 2009).<sup>5</sup> The accounts at  
26 issue are labeled “descriptive.” There are many descriptive accounts of function on  
27 the market. §5 discusses only two, namely, the organizational account (§5.1) and the  
28 selected effects account (§5.2). However, there is in addition the causal role account  
29 (e.g. Cummins, 1975), the biostatistical account (e.g. Boorse, 1977), various goal-  
30 contribution accounts (of which Boorse’s is one) (e.g. Adams, 1979), the propensity  
31 or life-chances account (e.g. Bigelow and Pargetter, 1987), the weak etiological the-  
32 ory (Buller, 1998), and the modal account (Nanay, 2010).<sup>6</sup> As those familiar with the  
33 extant function literature will recognize, each of these accounts lays some claim to  
34 explicating a concept of function that is applied at least within some subdiscipline of  
35 biology.

36 I belabor the points about function pluralism as well as descriptive accounts of  
37 function and I restrict focus to the organizational and selected effects accounts for two  
38 related reasons. First, I argue that cancer biologists ascribe normal functions to parts

---

<sup>4</sup>Note that some normal functions might not imply anything about the structure of the relevant part, say, if some behavioral or psychological functions are normal. However, because my focus is squarely within biology and because biological normal functions do imply normality in structure (Neander, 2002; Rosenberg and Neander, 2009) I continue to mention normal structure in my description of normal function.

<sup>5</sup>A related debate in the literature is whether pluralism is best understood as being about *interdisciplinary* differences in application of the concept(s) or as being about *intradisciplinary* differences (see Garson, 2018). The characterization in the main text of disputes in the literature is meant to be neutral on this debate concerning function pluralism. However, moving forward, I suppress relativizing to intrasubdisciplinary differences. I also at times suppress relativizing to intersubdisciplinary differences, where doing so does not threaten clarity.

<sup>6</sup>This list is not meant to be exhaustive.

of cancers (§3). Second, I argue that the organizational and selected effects accounts fail to be descriptive of cancer biology in this respect despite the claim (albeit made in passing) that they are descriptive of this subdiscipline in just this respect (§5). And, though I contend that my preferred account best describes normal function ascription in cancer biology, I too subscribe to function pluralism.<sup>7</sup>

In contrast to descriptive accounts, some accounts provide analyses of function that proponents claim biologists *should* take up and that stand to make their application of the concept uniform (most notably Millikan, 1984, 1989, 1999, 2002). While I focus on descriptive accounts, proponents of prescriptive accounts should find this paper fruitful for what it reveals about cancer biology. Prescriptivists who claim that cancer biologists should not ascribe normal functions to parts of cancers need to provide an argument why cancer biologists should not be searching for standards applicable to part-activity across a given type of cancer.<sup>8</sup> I argue in §6 that they do in fact search for those standards with the aim of inducing failure in part-activity, disposition, and/or structure as part of targeted treatment. And I argue that this practice is substantiated by efficiently homing in on mechanisms that make for promising targets of intervention.

## 2.2 Desiderata: Class Adequacy and Methodological Adequacy

Returning to descriptive accounts of function, there are at least two ways they can fail. First, they can be either too narrow or too broad with respect to the types of systems they consider.<sup>9</sup> An account is too narrow relative to a given subdiscipline of biology if it excludes systems of a type from having a type of function and biologists in that subdiscipline ascribe that type of function to parts of systems of the relevant type.

---

<sup>7</sup>There are three further reasons that I do not consider Cummins (1975)'s or Boorse (1977)'s account. First, regarding the former, Cummins's account does not aim to explicate the ascription of normal function. As such, his account is only relevant if it turns out that I am wrong concerning the ascription of normal functions to parts of cancers in cancer biology (*cf.* §6.1). Second, regarding the latter, Boorse's account defines normal function with a view to giving an account of a negative conception of health, that is, health as the *absence* of disease. As such, he is explicit that the activities or processes that promote pathologies are contrary to those that promote or sustain normal function (Boorse, 1977, 567). Since cancers are pathologies, they cannot have normal functions on Boorse's account by definition. Indeed, Boorse consistently assumes that cancer is an internal state of the organism which reduces normal functional efficiency or ability of some part(s) below some relevant threshold set by what is typical of the species—that is, he assumes that cancer is a disease (1976a, 66; 1977, 544, 547, 550, 560, 563; 1997, 47, 59-60, 96, 63 fn.46; 2014, 712). Moreover, he is explicit that cancers are non-functional down to the sub-cellular level (Boorse, 2002, 65 fn.49, 85-86 fn.63). Indeed, Boorse goes so far as to claim that we can apply the biostatistical account in explicating the concept of disease in order to adjudicate cases of pathologists' or researchers' atypical usage (2002, 53 fn.39). And I suspect he would find cancer biologists' ascription of functions to parts of cancers atypical in the relevant sense. That said, see Hausman (2012, 521-522, 534) for the claim that the notion of functional efficiency is applicable to parts of cancers. Third and finally, I argue elsewhere that difficulties type-individuating systems by appeal to reference-class are especially acute in the case of cancers due to their rank heterogeneity (Goldwasser, forthcoming). Thanks to an anonymous reviewer for pushing me to clarify these points and to include mention some of the descriptive accounts of function.

<sup>8</sup>Strictly speaking, this paper does not establish whether this claim or claims made in §6 (or §5.2) apply to Ruth Millikan's etiological, prescriptive account of *proper* function. Her technical notion of Normality is not restricted to the normality of normal functions ascribed in physiology and discussed in cancer biology nor obviously reducible to the normalizing force of evolution by natural selection. For instance, establishing what she calls a "reproductive family," to which proper functions are ultimately ascribed, can be done socially. A separate analysis is needed to discuss whether and how Millikan's view could deal with the ascription of normal functions to parts of cancers. I want to thank Colin Allen for pushing me to clarify this point.

<sup>9</sup>For an argument to this effect against Wright (1973)'s account of function, see Boorse (1976b). One can apply this strategy on the basis of the types of parts an account allows to have a type of function or the types of activities an account allows to count as a type of function. Regarding the former, an account that has it that, say, hearts do not have normal functions and aims to be descriptive inherits the burden of arguing that physiology does not ascribe normal functions to hearts. For an example of such an argument favoring Cummins's account, see Amundson and Lauder (1994).

1 For instance, say ecologists ascribe functions of a certain type to parts of ecosystems.  
2 If so, then any account of function that excludes ecosystems from having that type  
3 of function fails to be descriptive of ecology by being too narrow. By contrast, an  
4 account is too broad relative to a given subdiscipline of biology if it allows systems  
5 of a type to have a type of function and biologists in that subdiscipline knowingly  
6 decline to ascribe that type of function to parts of systems of the relevant type. For  
7 instance, say astrobiologists nowhere ascribe normal functions to parts of planetary  
8 systems—despite having ample opportunity to do so—because they think that those  
9 systems are just not such that their parts can embody a standard for activity. From the  
10 point of view of astrobiology, planets, asteroids, comets, circumstellar disks, etc. are  
11 just not the sorts of things that are *supposed* to perform certain activities or have cer-  
12 tain dispositions or structural features rather than others. If so, then any account that  
13 allows for the ascription of normal functions to parts of planetary systems fails to be  
14 descriptive of astrobiology by being too broad. Avoiding both of these pitfalls consti-  
15 tutes a desideratum on descriptive accounts to be extensionally adequate concerning  
16 the types of system to which a subdiscipline of biology ascribes a type of function—I  
17 call this “class adequacy.”

18 A second way descriptive accounts of function can fail is by providing condi-  
19 tions for the ascription of a type of function that are inconsistent with how biologists  
20 in a given subdiscipline actually go about ascribing those functions.<sup>10</sup> For instance,  
21 say that systematists neither explicitly nor implicitly appeal to natural selection nor  
22 need to when ascribing functions. If so, then any account of function that entails that  
23 ascription commits the ascriber to appealing to natural selection fails to be descrip-  
24 tive of cladistic systematics by being inconsistent with how functions are actually  
25 ascribed within that subdiscipline. Avoiding this type of criticism constitutes a second  
26 desideratum on descriptive accounts to remain consistent with methodology regard-  
27 ing ascription—I call this “methodological adequacy.” An account that is consistent  
28 with how a type of function is ascribed in a given subdiscipline of biology stands  
29 a chance of being descriptive relative to that subdiscipline. Even better is when an  
30 account provides conditions for function ascription that those in the subdiscipline  
31 *actually* apply. However, only bare consistency is necessary to satisfy methodological  
32 adequacy relative to a given subdiscipline.

33 Class adequacy and methodological adequacy together set a basic hurdle for  
34 descriptive accounts of function. Success both in identifying the class of systems  
35 whose parts are ascribed a type of function in a given subdiscipline of biology and  
36 in remaining consistent with how those functions are ascribed in that subdiscipline  
37 might not be sufficient to prove the soundness of a descriptive account. But they are  
38 necessary. When an account of function satisfies both desiderata relative to a subdis-  
39 cipline of biology, I say that it is descriptive of the ascription of a type of function  
40 relative to that subdiscipline.<sup>11</sup> In §5, I test accounts of normal function against these  
41 desiderata with respect to the ascription of normal functions to parts of cancers in

---

<sup>10</sup>For illustrative examples of arguments to this effect against Neander’s selected effects account, see Amundson and Lauder (1994); Griffiths (2006, 16–18).

<sup>11</sup>However, as I focus on the ascription of normal function, I often suppress relativizing to function-type when claiming that an account is or fails to be descriptive. And since I focus almost entirely on one type of case, namely, that in which cancer biologists ascribe normal functions to parts of cancers, I suppress relativizing to system-type and/or to intra-subdisciplinary boundaries when claiming that an account is or fails to be descriptive.

1 cancer biology (see also Goldwasser, forthcoming). For now, I turn to a representative  
2 example of such ascription.

### 3 **3 The Ascription of Normal Functions to Cancers**

4 A consistent challenge for cancer biologists is dealing with treatment relevant varia-  
5 tion among cancers. Here is a non-exhaustive list of clinically significant dimensions  
6 along which individual cancers can differ: anatomical site and tissue type of origin,  
7 genome, mutation rate, growth rate, tumor formation, incidence and rate of metasta-  
8 sis, the cancer microenvironment, and initiating agent. Like inquiry in any domain, a  
9 central task in cancer biology is finding within all of this variation sameness that is of  
10 causal and explanatory relevance. For instance, cancers have historically been clas-  
11 sified by anatomical site, tissue type, stage, and grade (Plutynski, 2018, especially  
12 Chapter 1 and the Appendix). A stage I, grade 1 lung adenocarcinoma is a cancer  
13 originating in glands (tissue) in the lung (site) that has yet to form a tumor (stage)  
14 and whose cells still resemble healthy, somatic cells (grade).

15 This standard classificatory scheme is effective at grouping cancers together and  
16 bears explanatory fruit. For instance, other properties relevant to treatment often clus-  
17 ter around tissue type, stage, and grade. Only some types of tissue form solid tumors,  
18 i.e., clumps of cancer-associated cells. Size is a property of solid tumors that is par-  
19 tially indicative of stage and is predictive of disease progression. And the degree of  
20 apparent similarity between cancer cells and healthy cells is predictive of growth rate  
21 and metastatic potential—grade 4 cancers with cells very unlike their healthy kin are  
22 likely to grow and metastasize more quickly and aggressively.

23 However, the standard scheme is not perfect (Plutynski, 2018, 2019). For  
24 instance, cancers originating in the same organ can be more similar genetically to  
25 those originating in a different organ than to each other. Precision oncology depends  
26 on targeting particular mutated genes and proteins. So, sameness in anatomical site  
27 of origin is not always explanatory or helpful for treatment. Luckily, the standard  
28 scheme represents only one of many tools for finding treatment relevant sameness  
29 among cancers.

30 One tool that cancer research shares with much of biology is the use of models.  
31 Following Godfrey-Smith (2006; 2009b) and Levy (2015), I assume a broad notion  
32 of “model” on which models are representations that abstract and idealize features  
33 of what they represent—their targets—with a view to predicting or explaining the  
34 behavior of those targets (*cf.* Weisberg, 2007). Models may be concrete, comprising  
35 a physical analogue of the target(s), or abstract, comprising a representation the vehi-  
36 cle of which is not supposed to be analogous to the target(s). Models may represent  
37 targets directly, say, by containing the part whose activity in the target is of interest  
38 or indirectly, say, by having the value of a variable go proxy for some quantifiable  
39 property of the target (e.g. size of a target population). Models predict or explain  
40 the behavior of their targets in much the way maps represent a territory—by resem-  
41 bling or being similar to those targets in ways relevant to a particular explanandum

1 of interest (Thomson-Jones, 2005; Elgin, 2017; Potochnik, 2017).<sup>12</sup> Often in cancer  
2 biology, the models used are concrete and may represent their targets directly or indi-  
3 rectly (however, for an example of an especially influential *abstract* model of cancer  
4 progression, see Armitage and Doll, 1954). These models are often populations of  
5 human or mouse cells with particular genomes that reliably produce tumor pheno-  
6 types of interest. Cancerous model cell-lines are injected into mice or zebrafish to  
7 see how well they progress *in vivo* or are grown into tumors in Petri dishes *in vitro*.  
8 As we will see immediately below and in §4.2, the use of models in cancer biology  
9 is integral to discovering part-activities that embody a standard for contributing to  
10 system-level activities of interest.


### 11 **3.1 Case Study: The Normal Function of Melanoma-derived sEV**

12 A second, related tool cancer research shares with much of biology is the ascription  
13 of normal functions, or so I now argue by example. A widely cited paper, Peinado  
14 et al (2012), claims to have “explored *the function* of melanoma-derived exosomes  
15 in the formation of primary tumors and metastases” (883; my emphasis). And Zhang  
16 and Yu (2019), reporting their results, say “[Peinado et al (2012)] have advanced  
17 our understanding of *the novel function* of exosomes in pre-metastatic niches” (458;  
18 my emphasis). The (novel) function explored and of which our understanding is  
19 advanced is the delivery of a protein to cells in bone marrow via membrane-bound  
20 packages produced mostly by late-stage melanomas (Figure 1). Through a series  
21 of experiments using cell-line and mouse models, Peinado et al identify a standard  
22 for the activity of small extracellular vesicles (sEV) or “exosomes” and whose per-  
23 formance results in greater primary tumor growth and more aggressive metastasis.  
24 Specifically, melanomas produce sEV carrying mesenchymal-epithelial transition  
25 factor (Met), an oncoprotein that can trigger several signaling pathways in cells  
26 (Organ and Tsao, 2011). Melanoma-derived sEV carrying Met travel through the  
27 blood to cells deep in bone marrow which have yet to differentiate. Receiving Met  
28 sets off a cascade of signaling in those progenitor cells that mobilize them to inflame  
29 distant organs, exhibit vascular leakiness in the tissues they migrate to, and produce  
30 vascular tissue. The result is pre-metastatic niche formation, which facilitates greater  
31 primary tumor growth and metastasis (Quail and Joyce, 2013; Mashouri et al, 2019;  
32 Gonzalez et al, 2020).

33 Peinado et al (2012) features the ascription of a normal function. Beyond use  
34 of the definite article, both Peinado and colleagues’ and Zhang and Yu’s talk of the  
35 (novel) function of melanoma-derived sEV generalizes over them without distin-  
36 guishing between later stages of melanoma, sEV that successfully deliver Met, sEV  
37 that are deformed or fail to carry Met, or melanomas that fail to produce any sEV  
38 at all. Generalizing over these divergences, effectively type-individuating melanoma-  
39 derived sEV in the process, is no accident (see also Zebrowska et al, 2020). In  
40 particular, generalizing afforded experimenters the opportunity and ability to identify  
41 a standard applicable to melanoma-derived sEV activity in relation to its contribution  
42 to pre-metastatic niche formation.

---

<sup>12</sup>Following Ronald N. Giere (1999, 2004) and Godfrey-Smith (2006, 2009b), I remain neutral on the exact resemblance or similarity relation that obtains between model and target.



**Fig. 1** (a) Melanoma-derived small extracellular vesicles (sEV) (here labeled “exosomes”) carry mesenchymal-epithelial transition factor (Met) (here labeled “MET”) to bone marrow progenitor cells (b) as well as sites of metastasis (here represented by the lungs) (d). The function ascribed to melanoma-derived sEV in Peinado et al (2012) is the delivery of Met to bone marrow progenitor cells (b), which mobilizes those cells (c) to inflame sites of metastasis, induce vascular leakiness (here labeled “extravasation”), and promote vascular growth (here labeled “proangiogenic”) altogether facilitating tumor growth and metastasis (here labeled “invasion”) (d). Adapted from Matsumoto et al (2017).

1 Let me explain. In the process of identifying the function, Peinado and colleagues  
 2 examined sEV production and Met delivery across early- and late-stage melanoma  
 3 patients as well as low and highly metastatic melanoma mouse models. They also  
 4 examined sEV production in melanoma mouse models designed to produce sEV  
 5 lacking Met, fewer sEV, or no sEV. The point was to home in on the mechanism(s)  
 6 responsible for sEV mediated pre-metastatic niche formation. This in turn required  
 7 the experimenters to re-identify sEV or mark their absence and to identify and relate  
 8 in a systematic way the effects of their presence or absence on niche formation. Some  
 9 of this was accomplished by tracking sEV-related proteins in blood. However, at least  
 10 some of it was accomplished by hypothesizing the activity melanoma-derived sEV  
 11 are *supposed* to perform for the cancer, positing the dispositions and/or structural  
 12 features that in the good case (for the cancer) allow them to perform that activity.  
 13 The hypothesis drew the experimenters to look for sEV in bone marrow and potential  
 14 sites of metastasis in patients and mouse models. It also drew them to infer from a  
 15 lack of sEV, reduced tumor growth, and reduced metastasis that they had successfully  
 16 disrupted the functional dispositions and/or structural features of melanoma-derived  
 17 sEV in models designed to produce sEV lacking Met, fewer sEV, or no sEV.

18 In confirming their hypothesis via intervention on cell-line and mouse models,  
 19 Peinado and colleagues show that deformed sEV and sEV that do not carry Met  
 20 are, in some minimal sense, *supposed* to deliver Met to bone marrow and are thus  
 21 in some minimal sense *supposed* to have the dispositions and/or structural features



1 that allow them to do so. I discuss in just what sense they are supposed to have  
2 these dispositions and/or structural features in §4.2. For now, what is important is  
3 that the generalization over both defective and non-defective sEV in the process of  
4 discovering their function and sites of possible clinical intervention suggests that the  
5 ascription identifies a standard for the activity of that part in relation to the system-  
6 level activity of interest. In which case, delivering Met to bone marrow is a normal  
7 function of melanoma-derived sEV.

8 Assuming Peinado et al (2012) is representative of the ascription of normal func-  
9 tions in cancer biology, such ascription informs the desiderata introduced in §2.2.  
10 Recall that class adequacy states that a descriptive account should be neither too nar-  
11 row nor too broad regarding the type of system to which the relevant subdiscipline  
12 of biology ascribes a type of function. If cancer biologists ascribe normal functions  
13 to parts of cancers then class adequacy dictates that an account is descriptive of can-  
14 cer biology only if it allows (parts of) cancers to have normal functions. Recall that  
15 methodological adequacy states that a descriptive account should not set out condi-  
16 tions for the ascription of a type of function that are inconsistent with how biologists  
17 within the relevant subdiscipline actually go about ascribing that type of function.  
18 Peinado and colleagues employed several methods en route to ascribing melanoma-  
19 derived sEV their normal function. However, as I argue (§4.2), the use of cell-line and  
20 mouse models was essential. If that is right and cancer biologists regularly employ  
21 models to identify normal functions of parts of cancer then methodological adequacy  
22 dictates that an account is descriptive of cancer biology only if it is consistent with  
23 the role modeling plays in ascribing normal function to parts of cancers. We now  
24 have two necessary conditions on accounts of function that aim to be descriptive of  
25 cancer biology. Such accounts are descriptive of cancer biology only if they allow  
26 for the ascription of normal functions to (parts of) cancers and only if they are con-  
27 sistent with the use of models in discovering those functions. In §5, I assess accounts  
28 on whether they satisfy both conditions. In §6, I consider and reject two objections  
29 to the claim that cancer biologists ascribe normal functions to parts of cancers. I now  
30 turn to introducing and applying the Modeling Account of Normal Function.

## 31 **4 The Modeling Account of Normal Function**

### 32 **4.1 Introducing the Account**

33 The Modeling Account of Normal Function (MA) is a member of a family often dis-  
34 cussed under the heading of “organizational accounts” (for instance Schlosser, 1998;  
35 McLaughlin, 2000; Mossio et al, 2009; see Garson, 2017a). Such accounts hold that  
36 the class of systems to which functions are ascribed in (much of) biology have the  
37 following two distinguishing features. First, they are organized in the sense that they  
38 are arranged into, in principle, distinct activity-based units at multiple levels. The  
39 cardiovascular system can be distinguished from other organ systems by the former’s  
40 transporting nutrients and waste to and from tissues; the heart can be distinguished  
41 from arteries and veins by pumping; the aortic valve can be distinguished from the  
42 ventricular septum by facilitating certain fluid dynamics between the left ventricle  
43 and the aorta, and so on. Second, these systems are self-maintaining in the sense that

1 the activity of their parts is what produces, reproduces, and maintains the arrange-  
 2 ment of parts and activities that constitute them. The heart’s pumping blood is part  
 3 of a process of nutrient and oxygen distribution which has as effects the production,  
 4 reproduction, and maintenance of blood and heart tissue. These in turn set up the  
 5 conditions for further pumping and are part of what leads to new organisms with new  
 6 hearts.

7 I call these “organized self-maintaining systems.” Consider as a contrast to these  
 8 systems a lit candle. A lit candle can be distinguished into wick, fuel, and flame. How-  
 9 ever, it cannot be decomposed into distinct, activity-based units at multiple levels:  
 10 there is only the single activity of consumption of fuel by flame. Moreover, lit can-  
 11 dles are not self-maintaining: consumption is not produced except by something else  
 12 lighting the wick and does not itself produce, reproduce, or maintain the fuel. Thus,  
 13 unlike, say, vertebrates, a lit candle is not an organized self-maintaining system.

14 MA differs from other organizational accounts, in particular the account put  
 15 forward by Mossio et al (2009) (§5.1), by claiming that the ascription of *normal*  
 16 function is part of a practice of modeling system-level activities constitutive of self-  
 17 maintenance relative to the type of system under investigation. MA proposes the  
 18 following condition: if a part-activity is a normal function then there is a class of mod-  
 19 els of the relevant system-level activity whose members are improved by including a  
 20 representation of that part and its activity. According to MA, biologists ascribe nor-  
 21 mal functions when they identify that the disposition(s) and/or structural feature(s)  
 22 of the function-bearing part are of causal relevance to an effect which, in turn, forms  
 23 part of an explanation of how organized systems of the type maintain themselves  
 24 (Mossio et al, 2009; Lennox, 2010). The cause of that effect is the part-activity the  
 25 relevant type of part standardly performs and the effect is the contribution that activity  
 26 makes to a system-level activity of interest (which, in turn, is at least partly consti-  
 27 tutive of self-maintenance). Biologists are motivated to make these ascriptions by an  
 28 interest in understanding how biological systems of a type work, where this means  
 29 how they effectively maintain themselves within highly constrained types of organi-  
 30 zation. Importantly, system type is not to be understood in terms of species or other  
 31 genera used to characterize *organisms*. MA is meant to apply to biological systems  
 32 while remaining neutral on whether those systems constitute individual organisms.  
 33 Cancers are a case in point.<sup>13</sup>

---

<sup>13</sup>One might object that a cancer cell’s or tumor’s satisfying conditions on counting as an organized self-maintaining system suffices for their counting as organisms. In which case, there is no need to remain neutral on whether cancer cells or tumors are individual organisms. In response, some putatively organized self-maintaining *biological* systems are not obviously organisms. For instance, ecosystems are biological systems comprised of multiple levels of in principle distinct, activity-based units whose activities produce, reproduce, and maintain the arrangements and parts of those systems. Yet, it is not obvious (and, thus, would require independent argument in favor of the claim) an ecosystem is a so-called “superorganisms” rather than a distinct kind of biological individual worth studying in its own right (see van Baalen and Huneman, 2014). Analogously, without independent reason for thinking of cancer cells or tumors as individuals, their being organized self-maintaining systems is insufficient to classify them as organisms. What makes cancers like ecosystems in this context is their being atavistic, effectively returning to a state in evolution between total unicellular anarchy and heavily enforced multi-cellular cooperation (Okasha, 2021). As such, the breakdown in the integrity and coherence of intraorganismal interactions exacerbates vagueness around what counts as an individual organism: a cancer cell could be an organism, part of a tumor, or a diseased part of its host. A tumor could likewise be an organism, an “ecosystem” of cancerous individuals and cancer-related entities, or a diseased part of its host. Fortunately, a merit of organizational accounts in general and MA in particular is that there is no requirement on these accounts to decide whether cancer cells or tumors are organisms so long as it is granted that they are organized self-maintaining systems. Thanks to an anonymous reviewer for pushing me to clarify this point.

1 Here is a more precise definition of MA, where  $\varphi$  stands for a type of part-  
 2 activity,  $p$  an individual part,  $S$  an individual system,  $A$  a type of system-level activity,  
 3  $M_{SA}$  a class of models indexed to systems of  $S$ 's type and their  $A$ -ing, and  $R_{p\varphi}$  a  
 4 representation indexed to  $p$  and its  $\varphi$ -ing:

5 (MA) An activity,  $\varphi$ , of a part,  $p$ , of a biological system,  $S$ , of a given type is a normal  
 6 function if and only if:

7 C1. the presence of parts of  $p$ 's type among systems of  $S$ 's type is an effect of the contribution  
 8  $p$ s make by tokening  $\varphi$  to the self-maintenance of  $S$ s; and

9 C2. there is a class of models,  $M_{SA}$ , such that, for any two models in that class,  $m_{SA}$ ,  $m'_{SA}$ ,  
 10 were  $m_{SA}$  to include a representation of  $p$  and its  $\varphi$ -ing,  $R_{p\varphi}$ , and were  $m'_{SA}$  not to include  
 11  $R_{p\varphi}$  then  $m_{SA}$  would better predict or explain how systems of type  $S$  maintain themselves  
 12 by tokening  $A$  than  $m'_{SA}$ .

13 (C1) is a metaphysical condition. It states that a normal function is a 4-place predi-  
 14 cate relating activity-type, part, system, and contribution to system self-maintenance  
 15 (*cf.* Weber, 2017). In particular, (C1) states that a requirement on a part's having a  
 16 normal function is that the part (or parts of the same type) is maintained, produced,  
 17 or reproduced in the system (or systems of the same type) as an effect of the activ-  
 18 ity of that (type of) part. This is just what we should expect of the functional parts  
 19 of organized self-maintaining systems. Again, the contribution to vertebrate self-  
 20 maintenance made by the heart's pumping sets up the conditions for further pumping  
 21 and is part of what leads to new vertebrates with new hearts. (C2) is a counterfac-  
 22 tual epistemic condition. It states that there is a class of models whose members  
 23 benefit from representing function-bearing parts and their activities, namely, those  
 24 which predict or explain system-level activities which are (partly) constitutive of self-  
 25 maintenance and for which the relevant function-bearing parts, per (C1), are specific  
 26 difference-makers.<sup>14</sup> Finally, as I am non-committal regarding the resemblance or  
 27 similarity relation that obtains between model and target (fn.12), I am correspond-  
 28 ingly liberal regarding representation.  $R_{p\varphi}$  can be a variable in a mathematical or  
 29 causal model, a physical analogue of part of the target, or anything in between.

30 Before moving on, I want to clarify (C2). It is not that the model which best  
 31 predicts performance of some system-level activity or best explains how a system  
 32 maintains itself via the performance of that activity is in every case a model that  
 33 includes representations of every part with a normal function. (C2) does not quan-  
 34 tify over all models of the relevant-system level activity in order to allow for cases  
 35 in which such a model excludes representations of parts when including them would  
 36 worsen the model. For instance, Setty et al (2008) provide a model of the organogen-  
 37 esis of the pancreas in mice which fails to represent adhesion proteins between the  
 38 cells that form the bud and eventually the organ. Because there are several such pro-  
 39 teins and their functional activity is thereby made redundant, no representation of any  
 40 particular adhesion protein is needed. In fact, Setty and colleagues' models represent

---

<sup>14</sup>On causation as difference-making see Woodward (2003); Halpern and Pearl (2005); Joseph and Judea (2005); Sartorio (2005); Loew (2019) and as applied to explanation in biology, see Woodward (2010). Following the latter, part of what I am claiming is that models that represent parts with normal functions as well as those functional activities are modeling specific causes of the relevant system-level activities. Thanks to an anonymous reviewer and Andrew Rubner for pushing me to clarify this point as well as the formulation of (C2).

1 the cells as held together but do not represent any such protein. Including a repre-  
2 sentation of some adhesion protein might well have impeded the model by including  
3 unnecessary detail in accounting for the underlying mechanisms of pancreas devel-  
4 opment in mice. (C2) can allow for this kind of case, since it tells us that, for every  
5 part that has a normal function, there is a class of models whose members benefit  
6 from including a representation of that part and its activity. In particular, the class of  
7 models is that of the relevant system-level activity for which the relevant part-activity  
8 is a difference-maker.

9 Before applying MA to the example of melanoma-derived sEV introduced in §3,  
10 I want to consider an example that is more germane to the function literature. The  
11 heart is ascribed its normal function when certain of its dispositions or structural fea-  
12 tures are identified as causally relevant to the transportation of nutrients and waste in  
13 vertebrates. Nutrient and waste transportation is an essential part of how vertebrate  
14 systems as a type achieve self-maintenance. This is the case for vertebrates whose  
15 hearts cannot pump blood too—they do not maintain themselves for very long after  
16 all. If this is right then there is a class of models of models of nutrient and waste  
17 transportation in the vertebrate circulatory system that should allow us to predict or  
18 explain the success or failure of that transportation in individual vertebrates in part  
19 by observing whether or how their hearts measure up in comparison to those mod-  
20 els. And we should be able to identify divergences in the dispositions or structural  
21 features of individual vertebrate hearts as such by appeal to those models. Models of  
22 vertebrate circulatory systems within the relevant class that include an abstracted or  
23 idealized representation of the vertebrate heart are preferable with respect to accom-  
24 plishing these predictive and explanatory tasks. Unsurprisingly, models of vertebrate  
25 circulatory systems in physiology and comparative anatomy in fact include such  
26 representations.

27 Importantly, how MA distinguishes normal functions and accounts for model-  
28 based explanations of the organization (or lack thereof) and self-maintenance (or lack  
29 thereof) of individual biological systems has the result that normal function is primar-  
30 ily an epistemic or explanatory notion rather than a metaphysical kind that picks out a  
31 category of activity. There might be no one thing or cluster of properties that picks out  
32 the normal functions from among all of the types of part-activities that are of inter-  
33 est to biology. Skepticism towards the metaphysical unity of normal functions places  
34 MA within a pragmatist tradition in philosophy of science and philosophy of biol-  
35 ogy in particular, according to which at least some scientific categories, rather than  
36 tracking unified kinds, group otherwise heterogeneous natural phenomena in a way  
37 conducive to scientific inquiry (Cummins, 1975; Hardcastle, 2002). This is not to say  
38 that some normal functions are not generally distinct in kind from some non-normal  
39 functions. However, as I show in §5, accounts that hold that, in the first instance, nor-  
40 mal functions constitute a metaphysical kind struggle to handle cases like Peinado  
41 and colleagues' ascription. It is to applying MA to this ascription that I now turn.

## 42 **4.2 Applying MA to Peinado and Colleagues' Ascription**

43 Before seeing whether the example provided by Peinado et al (2012) meets (C1) and  
44 (C2) of MA, I want to state explicitly that cancers are organized self-maintaining

1 systems. They can be decomposed into activity-based units at multiple levels. Can-  
2 cer associated fibroblasts can be distinguished from cancer cells by the support and  
3 protection the former provide the latter; sEV can be distinguished from cell nuclei  
4 by the former's disposing waste and carrying signaling proteins; Met can be distin-  
5 guished from  $\gamma$ -actin-1 by the former's sitting on the plasma membrane of cells and  
6 catalyzing signaling processes; etc. And the activities of these parts at both the cellu-  
7 lar and tumor level produce, reproduce, and maintain the arrangement of parts which  
8 constitutes the cancer (at least until patient death).

9 Let us apply MA to the example provided by Peinado et al (2012). Delivering Met  
10 to bone marrow is a normal function of melanoma-derived sEV if and only if the fol-  
11 lowing holds. First, (C1) the presence of melanoma-derived sEV among melanomas  
12 is an effect of pre-metastatic niche formation mediated by sEV Met delivery. Sec-  
13 ond, (C2) there is a class of models of melanoma pre-metastatic niche formation such  
14 that, for any two models within that class, were one model to include a representation  
15 of melanoma-derived sEV and their efficacious delivery of Met to bone marrow and  
16 were another model from the same class not to then the former model would better  
17 predict or explain pre-metastatic niche formation.

18 Starting with (C1), recall that Peinado and colleagues' ascription suggests that,  
19 in some minimal sense, melanoma-derived sEV are *supposed* to deliver Met to bone  
20 marrow. MA holds that they are supposed to do so in the sense that they make  
21 a contribution to melanoma self-maintenance—specifically to pre-metastatic niche  
22 formation—by delivering Met to bone marrow and that this results in their continued  
23 presence among melanomas. Consequently, we should expect there to be a correla-  
24 tion between the prevalence of sEV carrying Met and the persistence and propagation  
25 of individual melanomas. We can see this by looking more closely at the experi-  
26 ments that Peinado and colleagues carried out. Consider Table 1. The first three rows  
27 describe experiments showing that patients with late-stage metastatic melanoma and  
28 highly metastatic melanoma mouse models exhibit high concentrations of circulating  
29 sEV and sEV-related proteins compared to patients with stage I or stage II melanoma.  
30 These experiments suggest that melanoma-derived sEV perform a certain activity  
31 that has as effects disease progression and, in turn, their continued presence among  
32 melanomas.

33 As Met delivery is hypothesized to contribute to melanoma self-maintenance,  
34 MA predicts a correlation between a lack of sEV carrying Met and a drop in effica-  
35 cious propagation and persistence of melanoma. It holds that the part of melanoma  
36 self-maintenance constituted by pre-metastatic niche formation depends, at least in  
37 part, on the dispositions and/or structural features of melanoma-derived sEV that  
38 allow them to deliver Met. And it is in this sense that melanoma-derived sEV are  
39 supposed to have those dispositions and/or structural features. Consider the last two  
40 rows of Table 1. They describe experiments showing that reducing Met production  
41 and sEV production each result in smaller primary tumors and fewer metastases com-  
42 pared to highly metastatic mouse model and late-stage patients. These experiments  
43 suggest that pre-metastatic niche formation depends on Met delivery by melanoma-  
44 derived sEV. Taken together, Peinado and colleagues' experiments suggest that the

**Table 1.** Experiments in Peinado et al. (2012); mouse model cell-lines are in bold, human model cell-lines are in regular typeface.

Design	Model Cell-line	Results
Isolate melanoma-derived sEV plasma of human subjects.	N/A	High sEV protein (CD63, CD9, MHC-I) concentrations in late-stage melanoma patients with poor prognosis and highly metastatic mouse model.
Test for sEV related melanoma diagnostic signature using mass spectrometry and retrospective analysis.	<b>B16-F10, BF16-F1</b> , SK-Mel-28, SK-Mel-202, SK-Mel-265, SK-Mel-35, LLC	High concentrations of melanoma-specific protein (TYRP2) as well as proteins associated with oncogenesis (HSP90), cell maintenance under stress (HSC70), and inflammation (VLA-4) among late-stage melanoma patients compared to controls. TYRP2 discovered as diagnostic of progression past stage III.
Analyze distribution of sEV, gene expression, and metastatic burden in tissue of naive mice injected with sEV, first, once over a 24 hour and 48-hour period and then 3 times a week over a period of 19, 24, and 28 days.	<b>B16-F10, BF16-F1</b> , melan-a, SK-Mel-28, SK-Mel-202, LLC, MCF-7, SW480, SW620	Significantly greater distribution of sEV and gene expression for inflammation and extracellular matrix remodeling protein (S100A8, S100A9). When also injected with tumor cells, significantly greater metastatic burden in lungs and bone marrow for highly metastatic melanoma and mouse model.
Transplant bone marrow previously exposed to B16-F10 sEV or B16-F1 sEV for 28 days into lethally irradiated mice.	<b>B16-F10, BF16-F1</b>	Increased metastases in typical and atypical locations, increase primary tumor and metastatic growth, increased vasculogenic and hematopoietic bone marrow derived cell (BMDC) in mice with B16-F10 educated bone marrow.
Test Met expression in B16-F10 sEV and sEV derived from Met-knockdown-B16-F10 tumor cells. Test for downstream mediators in BMDCs. Compared results to late-stage melanoma patients.	<b>B16-F10, BF16-F1</b>	Significant increase in Met in untampered B16-F10 sEV. Significant increase in Met and vasculogenic and hematopoietic BMDC and mice injected with untampered B16-F10 sEV and tumor cells. Corroborated with high levels of Met and vasculogenic and hematopoietic BMDC in late-stage melanoma patients.
Test metastatic burden and mobilized BMDC in mice injected with B16-F10 sEV vs. Rab27a-knockdown B16-F10 tumor cells. Inject B16-F10 Rab27a-knockdown-B16-F10 sEV into mouse model.	<b>B16-F10, SK-Mel-28</b>	Increased metastatic burden and mobilized BMDC in mice injected with untampered B16-F10 sEV. Similar increases when injected directly with B16-F10 sEV from Rab27a-knockdown-B16-F10 tumor cells despite knockdown.

1 presence of melanoma-derived sEV among melanomas is an effect of pre-metastatic  
2 niche formation mediated by sEV Met delivery. Therefore, (C1) of MA applies.

3 Moving on to (C2), representations of sEV and Met delivery were integral to  
4 modeling pre-metastatic niche formation. We see this, again, by looking to Table  
5 1. The experiments described in the first three rows feature the use of cell-line and  
6 mouse models to identify mechanisms of pre-metastatic niche formation. Peinado  
7 and colleagues constructed models of melanoma as well as of lung, breast, and colon  
8 cancers with varying degrees of metastatic potential. The experiment described in the  
9 fourth row features the use of models to home in on the intermediate effect of interest,  
10 namely, bone marrow mobilization. In this case, the experimenters transplanted bone  
11 marrow that had previously received sEV derived from highly metastatic melanomas  
12 into mice. The experiments described in the last two rows feature the use of models  
13 to specify and confirm the activity melanoma-derived sEV performs. Experimenters  
14 reduced the production of Met or sEV in cell-line and mouse models, resulting in  
15 reduced bone marrow mobilization and, in turn, reduced pre-metastatic niche forma-  
16 tion. Every link in the inferential chain to the function ascription was forged by the  
17 construction and use of models. Importantly, the predictive and explanatory power of  
18 the models increased with the inclusion of a representation of sEV carrying Met and  
19 Met delivery. Had they not included that representation, albeit in the form of those  
20 very sEV, Table 1 shows that there is some model which would have predicted or  
21 explained as much or more about how the pre-metastatic niche is formed melanoma  
22 progression by including such a representation. Therefore, (C2) of MA applies.

23 MA applies to the example provided by Peinado et al (2012). I claimed in the  
24 previous section that the example is representative of normal function ascription in  
25 cancer biology. If this is right then MA satisfies both class adequacy and method-  
26 ological adequacy at least relative to cancer biology. MA satisfies class adequacy by  
27 avoiding restricting scope too much, for instance, to organisms or widening it too  
28 much, for instance, to lit candles. And it satisfies methodological adequacy by explic-  
29 itly assigning a role to modeling in ascribing normal functions in cancer biology. We  
30 thus have reason to believe that MA is descriptive of at least cancer biology. In what  
31 follows, I consider how other accounts of function—accounts which hold that normal  
32 functions are metaphysically distinct from other kinds of activity—fare with respect  
33 to satisfying class adequacy and methodological adequacy relative to cancer biology.

## 34 **5 Assessing Other Accounts of Normal Function**

35 In this section, I critically assess two other accounts in contrast to MA: the orga-  
36 nizational and selected effects accounts. Some of their proponents and critics have  
37 suggested in passing that one or both explicate the ascription of normal functions in  
38 cancer biology (for instance, see Garson, 2017a, 1100). In assessing whether these  
39 accounts meet both class adequacy and methodological adequacy relative to cancer  
40 biology, I uncover some difficulties each faces. I offer ecumenical readings on which  
41 modified versions might account for the ascription of at least some normal functions  
42 to cancers in cancer biology.

## 1 5.1 The Organizational Account

2 I start with the account initially put forward by Mossio et al (2009), as it is the  
3 closest relative of MA and most thoroughly developed and extended organizational  
4 account (*cf.* Schlosser, 1998; McLaughlin, 2000). According to Mossio and  
5 colleagues' organizational account (OA), a token trait,  $p$ , has a function,  $\varphi$ , within  
6 the organization,  $O$ , of a token system,  $S$ , if and only if:

- 7 O1.  $p$  exerts a constraint that contributes to the maintenance of  $O$  in  $S$ ;
- 8 O2.  $p$  is maintained under some constraints exerted by  $O$ ;
- 9 O3.  $S$  realizes organizational closure.<sup>15</sup>

10 Like MA, the organizational account holds that the systems to which functions are  
11 ascribed in (much of) biology are organized self-maintaining systems. Recall that  
12 biological systems are organized in the sense that they can, in principle, be decom-  
13 posed into activity-based units at multiple levels.<sup>16</sup> On OA, the organization of a  
14 system is the arrangement of traits and the coordination of the constraints that they  
15 exert. Constraints are influences that traits exert on ongoing processes. The influ-  
16 ence of a constraint is asymmetric: the ongoing process is altered by the trait while  
17 the trait is unaltered by the process and the trait cannot directly influence itself by  
18 exerting its constraint(s). For instance, the heart exerts a constraint on blood flow  
19 by pumping. Pumping alters blood flow while preserving the heart. And the heart  
20 only influences itself indirectly, through the mediation of other traits exerting their  
21 constraints. A system realizes organizational closure when its traits mutually con-  
22 strain each other, resulting in the maintenance of a particular organization among  
23 those traits. As Mossio et al (2009, 824-825) put it, organizational closure is "a circu-  
24 lar causal relation between some [higher-level] pattern or structure and [lower-level]  
25 dynamics and reactions" such that "a [lower-level] process is subject to closure in a  
26 self-maintaining system when [that process] contributes to the maintenance of some  
27 of the conditions required for its existence."<sup>17</sup> Finally, functions are relativized to  
28 individual systems and to the particular arrangement(s) of parts which allow those  
29 systems to realize organizational closure at a given moment. Mossio and colleagues  
30 call the latter, *momentary* arrangements "regimes of self-maintenance."

31 MA is in agreement with OA both concerning the class of systems that are given  
32 functional explanations in (much of) biology and concerning the relationship between  
33 function activity and system self-maintenance. Assuming cancers are organized self-  
34 maintaining systems, OA *appears* to satisfy class adequacy relative to cancer biology.  
35 However, OA is not, in the first instance, an account of normal function. To see this,  
36 consider the claim that my nose has the organizational function of holding up my

<sup>15</sup>Taken from Saborido et al (2016, 267). Variables replaced for consistency.

<sup>16</sup>Mossio and colleagues call this "organizational differentiation" (2009, 826).

<sup>17</sup>Montévil and Mossio (2015, 186) give a formal definition of organizational closure in terms of mutually dependent constraints acting on the thermodynamic flow of matter and energy through a system. A constraint,  $C_i$ , is subject to closure just in case I) to exert its influence,  $C_i$  depends directly on the influence of at least one other constraint in the closed system,  $C_j$ , and II) there is at least one other constraint in the closed system,  $C_k$ , that depends on the influence exerted by  $C_i$ .  $C_i$  depends directly on  $C_j$  just in case no other causal process mediates the influence of  $C_j$  on  $C_i$  during the time course during which  $C_j$  exerts influence over  $C_i$ . A more precise version of the example in the main text: systolic blood pressure within an appropriate range at some time depends directly on contraction of the heart's ventricles (at or immediately preceding that time) and several processes within the circulatory system depend on systolic blood pressure being within that range. Thus, systolic blood pressure within the appropriate range (at time  $t$ ) is subject to closure. Thanks to an anonymous reviewer for pushing me to clarify this point.



1 glasses. Suppose one regime of my self-maintenance—one particular, momentary  
2 organization of me—is me wearing my glasses. Call this “me+glasses.” (O1) My  
3 nose exerts a constraint, namely, holding my glasses up, that contributes to the main-  
4 tenance of me+glasses by allowing my eyes to foveate. (O2) My nose is maintained  
5 under some constraints exerted by me+glasses, say, by me+glasses navigating the  
6 world without walking into walls or falling off of cliffs. Finally, (O3) I as me+glasses  
7 realize organizational closure at least whenever the regime of me+glasses depends  
8 on my nose exerting some constraint that thereby indirectly sets up the conditions  
9 for its exerting that very constraint. My nose’s holding up my glasses contributes to  
10 the continued existence of me+glasses by allowing foveation and, thereby, indirectly  
11 sets up the conditions for my nose to hold up my glasses. So, my nose has the func-  
12 tion of holding up my glasses on OA. However, it is not the *normal* function of my  
13 nose to hold up my glasses. Contributing to the maintenance of me+glasses by hold-  
14 ing up my glasses is an incidental benefit of the structural features of that trait type.  
15 After all, a sufficiently low nasal bridge might fail to support my glasses (they do not  
16 have nose-pads) and, yet, be a fully functioning token of the type “nose.” In which  
17 case, it is not a normal function of the nose to hold up my glasses and, as stated, the  
18 conditions of OA are not sufficient for normal function.<sup>18</sup>

19 In fact, Mossio et al (2009, 830-834), using this very example, anticipate this gap.  
20 They claim that one can recover normal functions through what they call “primary  
21 functions.” More specifically, they claim that we can type-individuate systems by  
22 the set of regimes of self-maintenance that those systems must implement to remain  
23 viable or that require the least number of intervening part-activities to contribute  
24 to self-maintenance (Mossio et al, 2009, 829-832). A primary function of a trait is  
25 whatever activity or activities contribute(s) to the maintenance of regimes within that  
26 minimal set. So, the primary function of the heart is to pump blood because that is the  
27 constraint that it exerts which contributes to regimes within the minimal set charac-  
28 teristic of vertebrates. By contrast, even if the heart contributes to the maintenance of  
29 a human being by making a wooshing sound, its doing so is not its primary function,  
30 since pumping—which causes the sound—requires fewer intermediate activities to  
31 promote self-maintenance among the set of human beings. Mossio and colleagues  
32 claim that primary functions mostly overlap with normal functions. They also claim  
33 that the primary function of a trait is very likely what that trait was selected to do by  
34 natural selection (see §5.2). In effect, OA claims that normal functions supervene on  
35 primary functions, where those primary functions are selected by natural selection.

36 Unfortunately, recovering normal function through primary function will not  
37 work for cancer. First, even if parts of cancers have primary functions, it is not clear  
38 that their normal functions are what they were selected to perform. Setting that aside  
39 for now, a further problem for OA is that primary functions are not necessary for  
40 normal function ascription in cancer biology. Consider the tumor protein p53 gene  
41 (Tp53). In healthy cells, this gene encodes a protein, p53, that functions as a tumor  
42 suppressor by preventing cells with damaged DNA from replicating or by inducing  
43 programmed cell-death. Mutation of this gene in cancers is common, occurring in

---

<sup>18</sup>Thanks to both anonymous reviewers for pushing me to clarify how me+glasses realizes closure on OA and why this is nonetheless insufficient for holding up my glasses to count as a normal function of my nose.

1 over 50% of them, but not universal. Such mutation is not part of the minimal set of  
2 regimes of self-maintenance even within antecedently type-individuated cancers, for  
3 instance, breast cancer. Moreover, several cancers disrupt the production of p53 with-  
4 out exhibiting any mutated Tp53. Despite having no primary function on OA, several  
5 activities of mutated forms of Tp53 have been identified as standard across several  
6 types of cancer as well as making contributions to those cancers' self-maintenance.  
7 Tp53 mutants have thus been ascribed normal functions (for an overview, see Chiang  
8 et al, 2021). The point generalizes: if cancers have something in common, it is that  
9 they are exceptionally heterogeneous both in their traits and in how they maintain  
10 themselves. This heterogeneity means that, on OA, most if not all parts of cancers  
11 fail to have primary functions and, thus, cannot have normal functions. Yet, normal  
12 functions are ascribed to parts of cancers. This constitutes a failure to satisfy class  
13 adequacy relative to cancer biology.

14 At this point, one might object that insisting that normal functions are (properly  
15 thought of as) picking out type-level activities of parts or whole systems is undue.  
16 Once this requirement is dropped, OA can effectively recover normal function and  
17 its role in modeling in cancer biology (and beyond). Indeed, as Saborido et al (2016)  
18 put it, when accounting for the possibility of dysfunction:

19 The organizational interpretation of “correct functional behavior” is very different from the  
20 concept of “normal function” [...] we [do not] need to appeal to [...] an “idealized type” [...]  
21 to justify when an organism is functioning incorrectly. The normativity of organizational  
22 [functions and] malfunctions is based on the organizational properties of each token living  
23 being (115).

24 As Saborido and colleagues make clear, they do not understand the relevant func-  
25 tion concept to pick out standards of activity across types of system (or relative to  
26 types of part). Rather, correctness in functional behavior is determined within each  
27 individual organized self-maintaining system by the enforcement of a norm of a  
28 higher-order regulatory constraint onto one of its lower-order constraints.<sup>19</sup> What  
29 is more, one might point out that, building on Saborido et al (2016), Bich et al  
30 (2020) claim that we can develop models of “correct functional behavior” by attend-  
31 ing to the interactions of higher-order regulatory constraints and their impact on the  
32 lower-order constraints they regulate. Bich and colleagues use glycemia regulation  
33 as an example and sketch a model of the interactions of multiple higher-order con-  
34 straints which regulate glucose uptake, food ingestion and absorption, intracellular  
35 glycolysis, glycogenesis, glycogenolysis, gluconeogenesis, and glucose transport. As  
36 they put it “models relying on organizational closure can also *derive* these [homeo-  
37 static] relations [between the relevant higher- and lower-order constraints] from the  
38 underlying functional organization of the organism” (Bich et al 2020, 10; original  
39 emphasis). Once the requirement to account for type-level part and system activity  
40 has been dropped, OA appears able to provide a function concept whose applica-  
41 tion can not only distinguish functions from accidental benefits and dysfunctions but  
42 can even underwrite modeling the relevant parts, part-activities, and and system-level  
43 activities.

---

<sup>19</sup>Saborido et al (2016, 109-111) call such enforcement in the context of system viability “functional presupposition.”

1 There are at least two things to say in response. First and less importantly, by their  
2 own admission Bich et al (2020, 2, 11-12) do not “provide a full-fledged model of the  
3 regulation of blood glucose concentration” but only “preliminary guidelines” for con-  
4 structing such models. Second and more importantly, even if they had they provided  
5 a full-fledged model of glycemia regulation, the model could not apply to more than  
6 one system (or momentary regime of self-maintenance) without assuming a shared  
7 minimal set of regimes of self-maintenance across the relevant type. I grant that some  
8 such minimal set—one which includes regulatory mechanisms for glucose concen-  
9 tration in blood—exists at least for vertebrates. Thus, a model of glycemia regulation  
10 inspired by organizational principles is likely to apply across several biological taxa.  
11 But, as I argued in relation to the case of mutated Tp53, the rank heterogeneity of  
12 cancers precludes their sharing such a minimal set except possibly at extremely high  
13 levels of generality, for instance, as involving the arrest of programmed cell death.  
14 This means that models of system-level activities of cancers that are constructed fol-  
15 lowing Bich and colleagues’ guidelines and which appeal to functions in accordance  
16 with OA are unlikely to find application across the relevant type(s) of cancer. Yet,  
17 as Peinado and colleagues’ ascription shows, cancer biologists provide functional  
18 explanations of the relevant system-level activities across the relevant type(s). If OA  
19 is to remain a descriptive account of function, it cannot recommend that cancer biol-  
20 ogists cease giving explanations at the level of types of cancer on pain of flouting  
21 methodological adequacy.<sup>20</sup>

22 Here is an ecumenical move in anticipation of the following subsection: either  
23 the traits of cancers that have normal functions are selected to perform those func-  
24 tions or they are not. If they are selected to perform those functions then a modified  
25 form of OA can lean on a selected effects account of normal function to be presented  
26 immediately below (§5.2). This new organizational-*cum*-selected-effects account of  
27 normal function, call it OA+SE, is similar to MA to the extent that OA+SE, like MA,  
28 makes reference to a part’s contribution to an organized system’s self-maintenance.  
29 On the assumption that the relevant traits are selected to perform their normal func-  
30 tions, OA+SE satisfies class adequacy relative to cancer biology. However, it satisfies  
31 methodological adequacy only if it is consistent with the role modeling plays in the  
32 ascription of normal function in cancer biology. On the other hand, if, as I suspect,  
33 traits of cancers with normal functions are not always or even typically selected to  
34 perform those functions then, to recover them, a proponent of OA can appeal to  
35 whatever principles seem to be at work in ascribing them in cancer biology. If I am  
36 right then they are ascribed when an activity is identified as causally relevant to an  
37 effect that is, in turn, part of how cancers of a certain type maintain themselves. And  
38 if I am right, this sort of causal relevance is (at least very often) captured through  
39 modeling the mechanism(s) that produce(s) the effect of interest. In which case, this  
40 second modified form of OA, call it OA+M, could appeal to the role modeling plays  
41 in ascribing normal functions. I do not see how going in for OA+M avoids collapse  
42 into MA.<sup>21</sup>

---

<sup>20</sup>Thanks to an anonymous reviewer for this objection.

<sup>21</sup>Thanks to an anonymous reviewer for pushing me to clarify this point.

## 5.2 The Selected Effects Account

Moving on, according to the standard version of the selected effects account (SE), normal functions are activities for which the function-bearing part was selected by natural selection. I consider SE for two reasons. First, because it is not explicitly tied to health such that cancers, in virtue of being pathologies, fail to have normal functions by definition (*cf.* fn.7). Second, I consider SE because at least one of its proponents has suggested that SE may be descriptive relative to cancer biology (Garson, 2017a, 1100). Neander (1991a,b, 2002, 2017a,b) was a longstanding advocate of a descriptivist SE, claiming the account captures at least what physiologists and neuro-physiologists mean by “normal function” (2017b, especially Chapter 4). According to Neander:

(SE) It is the/a [normal] function of an item ( $p$ ) of [a system] ( $S$ ) to do that which items of  $p$ 's type did to contribute to the inclusive fitness of  $S$ 's ancestors, and which caused the genotype, of which  $p$  is the phenotypic expression, to be selected by natural selection (1991a, 174; variables replaced for consistency).

On SE, the ascription of normal function implies that the function-bearing part as well as its disposition and/or structure should be stable across populations which share unbroken lineages of selection for the functional activity (see Neander and Rosenberg, 2012, 617-622).<sup>22</sup> This implication is grounded in the evolutionary history of the part, which the account claims is explanatory of its function.<sup>23</sup> For instance, certain cells in the optic tectum of the common toad (*B. bufu*) have the normal function of responding to prey-like objects in their receptive fields because cells of that type contributed to the inclusive fitness of ancestral common toads by doing so and thereby caused the genotype, of which those cells are the phenotypic expression, to be selected by natural selection (Neander, 1991a, 2017b). Contemporary common toads that share an unbroken lineage with the relevant population of ancestral common toads should therefore have optic tecta containing cells that respond to prey-like objects and those cells should have the dispositions and/or structural features that allow them to do so.

SE is consistent with the methodological role played by the ascription of normal function in cancer biology. It holds that normal functions are ascribed as part of the practice of modeling species. Identifying normal functions for the construction of these “species designs” depends on a variety of experimental tools. In fact, modeling itself is among these tools. For instance, modeling the mechanism(s) of prey detection, like modeling that of pre-metastatic niche formation, appears integral to ascribing normal function (Neander, 2017b, especially Chapter 5). The normal functions ascribed are then represented in *further* models, namely, species designs. Models are thus given a considerable role by SE. The account stands to satisfy methodological adequacy relative to cancer biology.

Shifting focus to class adequacy, though Neander herself does not extend the ascription of normal function to pathologies (2017b, 62-63), she acknowledges that systems other than organisms might be subject to selection (2017b, 21). Bracketing

<sup>22</sup>Thanks to an anonymous reviewer for pushing me to clarify this point.

<sup>23</sup>The selected effects account is not the only one inspired by evolutionary theory (see, for instance, Bigelow and Pargetter, 1987; Buller, 1998; Kitcher, 1993). However, I leave a full treatment of those accounts for another occasion.

1 the fact that they are pathologies, if cancers are among the class of systems subject  
2 to natural selection then their parts might have normal functions on SE. The account  
3 thus *appears* to satisfy class adequacy. As it turns out, a recent trend in cancer biology  
4 has seen researchers take up an evolutionary perspective on cancer. This perspective  
5 bears explanatory fruit by framing cancer progression as a process of clonal evolution  
6 (Greaves and Maley, 2012; Plutynski, 2017, especially Chapter 5, Plutynski, 2018;  
7 Bozic and Wu, 2020). Cancer cells and their clonal progeny are thought to be subject  
8 to the selection pressures imposed by a hostile environment in the form of limited  
9 resources, immune response, and treatment. They are also subject to environmental  
10 constraints like the physical structure of their microenvironment. To persist and prop-  
11 agate, cancers must effectively balance the use of resources, expansion, and evasion  
12 (Hausser and Alon, 2020). Cancers appear to meet the conditions necessary for being  
13 subject to natural selection: they exhibit inherited variation, differential fit between  
14 system and environment, and differential retention of systems or traits. Those traits  
15 that are differentially retained are selected by natural selection (Lewontin, 1970). In  
16 which case, those traits have whatever normal function they were selected to perform.

17 Unfortunately, SE still threatens to flout class adequacy relative to cancer biol-  
18 ogy. Satisfaction of the conditions for being subject to natural selection is a matter of  
19 degree (Godfrey-Smith, 2009a). And several types of cancers do not meet these con-  
20 ditions except minimally (Germain, 2012; Germain and Laplane, 2017; *cf.* Lean and  
21 Plutynski, 2016). At the cellular level, the parts of cancers that are ascribed normal  
22 functions are often enough the product of genetic drift or genetic hitchhiking with-  
23 out necessarily being fully co-opted (Germain, 2012, 806). And at the tumor level,  
24 these parts are often enough neither heritable nor recapitulated in metastases nor the  
25 product of competition (Germain and Laplane, 2017, 281-287). In which case, it is  
26 at least possible that some parts of cancers have normal functions despite not being  
27 selected for by natural selection. But, on SE, a necessary condition on a part's having  
28 a normal function is its being selected for by natural selection. Thus, allowing the  
29 ascription of normal functions to pathologies is unlikely to allow SE to satisfy class  
30 adequacy relative to cancer biology.<sup>24</sup>

31 A proponent of SE might broaden the scope of selection mechanisms beyond  
32 natural selection. Garson's generalized selected effects account does just this (2011;  
33 2012; 2016; 2017b). Moreover, he claims that his account can capture the ascription  
34 of normal function to parts of cancers so long as those parts are adaptations or are  
35 retained or reinforced over others (Garson, 2017a, 1100). Differential retention/re-  
36 inforcement need not involve heritability, recapitulation, competition, or that parts  
37 be retained *after* exaptation. In fact, differential retention/reinforcement might well

---

<sup>24</sup>A separate but, to my mind, equally pressing issue stems from the fact that SE and other etiological accounts assume a distinction between system and environment. Drawing this distinction is especially tricky in the case of cancers such that doing so as part of the recent evolutionary turn in cancer biology is likely an idealization on the part of researchers. After all, as the case presented by Peinado and colleagues shows, the relevant system can be spatially discontinuous and distributed across the "environment"—in this case, the body. Given that distinguishing system from environment is an idealization, at least in the case of cancer, those ascriptions that rely on treating the normal functions of cancers as effects of clonal evolution are likely part of the process of modeling cancers. It is then not clear that they pick out a kind of activity that is metaphysically distinct from other kinds of part-activity. And though this may not go against the letter of accounts like Neander's, it surely goes against the spirit of such accounts. For an argument to this effect and an independent argument favoring the application of organizational accounts of function to cancer, see Bertolaso (2013).

1 explain how function-bearing parts are initially co-opted in cancers. Garson’s account  
2 appears able to satisfy class adequacy relative to cancer biology.

3 Here is an ecumenical move: a proponent of SE can combine Garson’s liberal  
4 account of selection with Neander’s claims concerning the role of modeling in ascrib-  
5 ing normal functions. The resulting modified selected effects account appears to  
6 satisfy both class adequacy and methodological adequacy relative to cancer biology.  
7 The account might still exclude the ascription of normal functions to parts of cancers  
8 that benefit those cancers by means of performing the relevant activity but are not yet  
9 retained or reinforced over others. By contrast, MA does not exclude the ascription of  
10 normal functions to these parts. This is because, on MA, self-maintenance does not  
11 imply retention or replication of a part (or system) *over* that of another. MA’s lower-  
12 ing the bar on normal function ascription is an advantage to the extent that it captures  
13 more of the normal functions ascribed in cancer biology than this Garson-Neander  
14 hybrid SE.<sup>25</sup>

## 15 **6 Objections: Loose Talk and Going Wrong**

16 I have so far argued for MA’s superiority as a descriptive account of normal function  
17 relative to cancer biology. Here, I consider and respond to two possible objections  
18 to the claim motivating my argument, namely, that cancer biologists ascribe nor-  
19 mal functions to parts of cancers. Each objection corresponds to class adequacy and  
20 methodological adequacy. First, one might claim that cancers are just not the type of  
21 system that can appropriately be ascribed normal functions. Any appearance to the  
22 contrary reflects a loose way of speaking on the part of some cancer biologists. In  
23 which case, MA is overly broad relative to cancer biology. I call this “the objection  
24 from loose talk.” Second, one might allow that parts of cancers are ascribed nor-  
25 mal functions but deny that what is being explained are the contributions those parts  
26 make to the self-maintenance of the cancer. Rather, the ascription serves to identify  
27 the normal function of healthy variants in the context of pathology. In which case,  
28 MA mislocates the relevant explanandum in cancer biology. I call this “the objection  
29 from going wrong.”

### 30 **6.1 The Objection From Loose Talk**

31 Starting with the objection from loose talk, one might claim that cancer biologists do  
32 not ascribe normal functions to parts of cancers at all. This objector claims that there  
33 is no reason to think that the ascription of “the function” or “the novel function” to a  
34 part of cancer identifies a standard for its activity, dispositions, or structure. At most,  
35 these functions, like those ascribed in cladistic systematics (§2.1), identify actual or  
36 typical causes of disease progression. Moreover, cancer biologists appear to reserve  
37 talk of “normal function” for the activities of healthy variants when contrasting those  
38 activities with that of parts of cancers.

---

<sup>25</sup>It is open to a proponent of the Garson-Neander account to dispute whether exapted parts that have not become adaptations have any normal functions. In fact, a proponent of the Garson-Neander view might well claim that, prior to retention/reinforcement, the relevant activities are at most systematic/causal role functions (fn.7). Addressing this claim goes beyond the scope of this paper.

1 In response, there is at least one reason for trying to identify standards for part-  
2 activity, dispositions, and/or structure among types of cancers. Namely, doing so  
3 successfully provides viable avenues for treatment in virtue of predicting and/or  
4 explaining how types of cancer achieve self-maintenance. The ultimate aim of cancer  
5 biology is the development of effective clinical interventions. This aim is prob-  
6 lematized by the heterogeneity that cancers exhibit (§§3.1, 5.1). And it is further  
7 problematized by cancers effectively exploiting that heterogeneity. The result is that  
8 the more thoroughly a cancer establishes itself in its host the more specialized the  
9 knowledge required to undermine its deleterious features becomes. At the same time,  
10 the heterogeneity that cancers exhibit and exploit is limited by the evolutionary his-  
11 tory of the organism, the mutations driving the cancer, the rate at which the cancer  
12 mutates, the organism's environment, and much more besides. These limits do not  
13 group traits into anything resembling unified kinds but can be used as guideposts  
14 to common vulnerabilities among cancers. The plurality of classificatory schemes  
15 (§3) and scientific tools like modeling (§4.2) allow researchers to find and exploit  
16 these common vulnerabilities in a principled way. I submit that knowledge of how  
17 to undermine particular traits or mechanisms across types of cancer is often gathered  
18 by modeling those traits and mechanisms under the guise of normal function. These  
19 models cut across instances in which the relevant parts or mechanisms fail to benefit  
20 the cancer. This is partly because clinicians do not necessarily want to rectify those  
21 failures. Nonetheless, in seeking to undermine the disease, the models cancer biolo-  
22 gists build capture standards for the activities, dispositions, and/or structural features  
23 of those parts. And they do so effectively by employing the notion of normal function.

24 I want to stress that giving up on normal functions here threatens to deprive us of  
25 an extremely useful explanatory tool in the cancer biologist's toolbox. Even if their  
26 ascription is an in principle dispensable part of cancer biology, the case presented by  
27 Peinado et al (2012) shows that normal functions serve as an effective guide to at least  
28 some commonalities of clinical significance among cancers. Peinado and colleagues  
29 are not alone in this practice. Indeed, cancer biologists have ascribed a number of pro-  
30 oncogenic, pro-tumorigenic, and pro-metastatic functions to signaling and receptor  
31 proteins, catalyzing enzymes, lipoproteins, growth factors, and so on (Goel and Mer-  
32 curio, 2013; Bång-Rudenstam et al, 2019; Gerlach and Weigmann, 2019; Ilhan et al,  
33 2020; Peng et al, 2020; Yu et al, 2020). Cancer biologists in this emerging tradition  
34 are aiming to predict and/or explain the way these parts benefit cancers through those  
35 parts' activity *at the type-level* and are, unsurprisingly, aiming to discover the dispo-  
36 sitions and structural features by which those parts benefit those cancers, again, *at*  
37 *the type-level*. This is because discovering these type-level dispositions and features  
38 give those working in precision oncology a clinical foothold in the form of targets for  
39 intervention. Moreover, knowing that the relevant part of an individual cancer is not  
40 performing its normal function can aid in the discriminatory use of the relevant inter-  
41 ventions, making precision oncology that much more precise (and effective). This is  
42 exactly what we should expect if MA is right: it is the role of normal functions to tell

1 us what these parts are supposed to do, in this case so that we can undermine their  
2 ability to do what they are supposed to.<sup>26</sup>

3 I suspect that resistance to allowing normal functions to be ascribed to parts of  
4 cancers rests partly in conflating distinct (albeit related) categories of biological nor-  
5 mativity: normality and health.<sup>27</sup> Health is a state that is good to be in. And what is  
6 healthy is conducive to being in that state. The heart's pumping blood (efficiently) is  
7 healthy. But health is not synonymous with normality where normality merely sets  
8 standards among a type of system (*cf.* Boorse, 1977). Consider an Olympic cyclist  
9 whose leg muscles are quickly atrophying. The state of his leg muscles is unhealthy  
10 despite crossing into what is normal for human beings (of his age and sex) on a  
11 number of dimensions, e.g., volume or mass, as they wither. By contrast, a second  
12 Olympic cyclist in her prime will have leg muscles that differ from what is normal on  
13 those dimensions and many besides. Normality and health can come apart. Normal-  
14 ity sets standards across types of system and some parts of cancers exhibit activities,  
15 dispositions, and/or structural features that embody those standards. That cancers are  
16 pathological and that cancer biologists often use "normal" to mean healthy in no way  
17 undermines the propriety of ascribing normal functions to parts of cancers.

## 18 **6.2 The Objection From Going Wrong**

19 The objection from going wrong allows that cancer biology exhibits the ascription  
20 of normal functions to parts of cancers. However, the objector denies that the normal  
21 functions ascribed are activities that contribute to the self-maintenance of any pathol-  
22 ogy. Rather, in every case, they are activities that would contribute to the organism  
23 but are performed in an unfortunate context. Following Matthewson and Griffiths  
24 (2017), I consider this a way of "going wrong" in the sense of violating some biolog-  
25 ical norm. Matthewson and Griffiths list four ways of going wrong: i) malfunction  
26 (i.e. pathology), ii) performance of a normal function in a non-hostile environment  
27 that is nonetheless alien and/or systematically impedes performance (2017, 454) iii)  
28 performance of a normal function in a hostile environment, and iv) performance of a  
29 normal function in a non-alien, non-hostile environment that is nonetheless unlucky.

30 In the case of cancer, the objector might say that cancers are nothing more than  
31 ways of going wrong for the organisms that contract them. Any ascription of a nor-  
32 mal function to a part of cancer is at most a recognition of the activity which that  
33 part is supposed to perform in healthy variants. The activity of sEV in melanoma  
34 progression is not functional because it promotes tumor growth and metastasis. It is  
35 functional only because it aids the growth of vascular tissue and immune response  
36 in healthy individuals (Neander, 2017a, 1155, fn.24). Unfortunately, in the case pre-  
37 sented by Peinado et al (2012), vascular growth and immune response occur in light  
38 of the activity of cancerous cells. That is why sEV activity in the case presented in  
39 §3.1 is considered both functional and pathological: sEV are doing what they are

---

<sup>26</sup>Thanks to an anonymous reviewer for pushing me to clarify this point and allowing me the opportunity to stockpile these examples in the main text.

<sup>27</sup>Part of what is at issue in this discussion is how cancer biologists talk about the activities of parts of cancers. However, it would be premature to claim that because cancer biologists often use "normal" to talk about healthy activities in contrast to pathological ones it follows that they do not ascribe normal functions to parts of cancers, where normal functions embody a standard for part-activity, disposition, and/or structure.



1 supposed to do but in an alien, hostile, or unlucky context. So, the objection goes,  
2 there is no ascription of normal functions to parts of cancers just as such. There is  
3 only the ascription of normal functions to parts of non-pathological systems whose  
4 performance sometimes, unfortunately, ends up promoting pathologies.

5 In response, it is often the case that the activities performed by parts of cancers  
6 are the same as or similar to those performed by healthy variants. However, even  
7 when this is the case, these overlapping activities are not necessarily what is being  
8 identified as a normal function. Claiming otherwise threatens to belie the object of  
9 research of which Peinado et al (2012) is a representative example, namely, identi-  
10 fying what parts of cancers standardly do *for those cancers*. The normal functions  
11 ascribed to sEV, microRNAs, co-opted cells, etc. make contributions that are key to  
12 carcinogenesis, tumorigenesis, and metastasis. Moreover, when the relevant activity  
13 is *not* found among healthy variants, the function is labeled “novel.” MA can capture  
14 both of these facts: the activity is identified as a normal function by figuring out, ide-  
15 ally by means of modeling, how its performance contributes to the relevant type of  
16 cancer, specifically to self-maintenance across that type. Thus, it is not the case that  
17 the ascription of normal functions to parts of cancers is no more than the recognition  
18 of the exercise of normal functions of healthy variants “going wrong.”

19 I suspect the temptation to assimilate normal functions of parts of cancers to  
20 overlapping activities of healthy variants rests partly in an attempt to hold onto meta-  
21 physical unity among normal functions. Several philosophers are committed to the  
22 claim that the category of normal function is real or mind-independent (for instance,  
23 Neander, 2017b, especially Chapter 3). This means that the kind of activity identified  
24 with those functions is metaphysically distinct in virtue of having a certain prop-  
25 erty or properties, say, being selected for, being species-typical, having a particular  
26 purpose within the organism, etc., which other kinds of activity lack. If so then that  
27 property or those properties stand(s) to bear epistemic fruit and to have certain nor-  
28 mative upshots. However, this hope belies an overly simplistic view of explanatory  
29 categories in science and threatens to get in the way of clinically significant discov-  
30 ery. As we saw in §5, attempts at analyses of normal function in terms that set them  
31 apart metaphysically ran into difficulties accounting for application of the concept by  
32 cancer biologists. Moreover, many explanatory categories in science do not admit of  
33 conceptual analysis, including the category of cancer itself (Plutynski, 2018)! Rather  
34 than forcing consistency in the name of identifying a kind of activity at the metaphys-  
35 ical level, philosophers working in the literature on function should use cases like  
36 that discussed in §3 as an opportunity to seriously reflect on the higher-order goals  
37 of supplying a unified account of normal function.

## 38 7 Conclusion

39 I have argued that we need an account of normal function that satisfies class ade-  
40 quacy and methodological adequacy relative to cancer biology. I claimed that the  
41 Modeling Account of Normal Function does so and applied it to what I take to be  
42 a paradigmatic example of cancer biologists ascribing normal functions to cancers.  
43 Other accounts of normal function struggle but can be modified to capture at least  
44 some of the normal functions these researchers ascribe. Whatever account is best

1 suited to explicate the ascription of normal function to parts of cancers, that we need  
 2 one has at least one upshot for the philosophy of biology. The contemporary literature  
 3 on function has been around for a half-century. Yet, there has been little sustained  
 4 discussion of the functions—normal or otherwise—of complex pathologies except as  
 5 counterexamples. This is the case despite there being ample evidence that, say, cancer  
 6 biologists ascribe normal functions to parts of pathologies. While some might claim  
 7 that the lack of discussion is due to pathologies being processes that are contrary to  
 8 normality at the metaphysical level (Boorse, 1977, 1997; Garson, 2013), I believe it  
 9 is a product of an overemphasis on the study of organisms. Organisms are an impor-  
 10 tant object of study in biology. However, part of what is interesting about organisms  
 11 is not distinctive of them, namely, that they are organized in ways that allow them to  
 12 sustain themselves. Others have drawn on this common feature of biological systems  
 13 to make sense of the ascription of function to, for instance, ecosystems (Nunes-Neto  
 14 et al, 2014; Dussault and Bouchard, 2017; Morrow, forthcoming). MA attempts to  
 15 draw on these commonalities to make sense of the ascription of normal functions to  
 16 parts of cancers. Regardless of whether the account succeeds, this paper will have  
 17 served its purpose if it galvanizes philosophers to find an account of function that  
 18 carves Nature at her “oncological joints.”<sup>28</sup>

## 19 **References**

- 20 Adams FR (1979) A goal-state theory of function attributions. *Canadian Journal of*  
 21 *Philosophy* 9(3):493–518. <https://doi.org/10.1080/00455091.1979.10716265>
- 22 Allen C, Bekoff M (1995) Biological function, adaptation, and natural design.  
 23 *Philosophy of Science* 62(4):609–622. <https://doi.org/10.1086/289889>
- 24 Amundson R, Lauder GV (1994) Function without purpose. *Biology and Philosophy*  
 25 9(4):443–469. <https://doi.org/10.1007/BF00850375>
- 26 Armitage P, Doll R (1954) The age distribution of cancer and a multi-stage theory of  
 27 carcinogenesis. *British Journal of Cancer* 8(1):1–12. [https://doi.org/10.1038/bjc.](https://doi.org/10.1038/bjc.1954.1)  
 28 [1954.1](https://doi.org/10.1038/bjc.1954.1)
- 29 Arp R (2007) Evolution and two popular proposals for the definition of function.  
 30 *Journal for General Philosophy of Science* 38(1):19–30. [https://doi.org/10.1007/](https://doi.org/10.1007/s10838-006-9008-3)  
 31 [s10838-006-9008-3](https://doi.org/10.1007/s10838-006-9008-3)
- 32 van Baalen M, Huneman P (eds) (2014) Thematic Issue on Organisms as Ecosystems  
 33 / Ecosystems as Organisms [Special Issue]. *Biological Theory*, vol 9(4).
- 34 Bertolaso M (2013) On the structure of biological explanations: Beyond functional  
 35 ascriptions in cancer research. *Epistemologia* 36(1):112–130. [https://doi.org/10.](https://doi.org/10.3280/EPIS2013-001008)  
 36 [3280/EPIS2013-001008](https://doi.org/10.3280/EPIS2013-001008)

---

<sup>28</sup>For comments and discussion I wish to thank Colin Allen, Anya Plutynski, Andrew Rubner, and two anonymous reviewers. I would also like to thank my partner, Morgan Misko, for her tireless support.

- 1 Bich L, Mossio M, Soto AM (2020) Glycemia regulation: From feedback loops to  
2 organizational closure. *Frontiers in Physiology* 11. [https://doi.org/10.3389/fphys.](https://doi.org/10.3389/fphys.2020.00069)  
3 [2020.00069](https://doi.org/10.3389/fphys.2020.00069)
- 4 Bigelow J, Pargetter R (1987) Functions. *Journal of Philosophy* 84(4):181–196. <https://doi.org/10.2307/2027157>  
5
- 6 Boorse C (1976a) What a theory of mental health should be. *Journal for the Theory of*  
7 *Social Behaviour* 6(1):61–84. [https://doi.org/10.1111/j.1468-5914.1976.tb00359.](https://doi.org/10.1111/j.1468-5914.1976.tb00359.x)  
8 [x](https://doi.org/10.1111/j.1468-5914.1976.tb00359.x)
- 9 Boorse C (1976b) Wright on functions. *Philosophical Review* 85(1):70–86. <https://doi.org/10.2307/2184255>  
10
- 11 Boorse C (1977) Health as a theoretical concept. *Philosophy of Science* 44(4):542–  
12 573. <https://doi.org/10.1086/288768>
- 13 Boorse C (1997) A rebuttal on health. In: Humber JM, Almeder RF (eds) *What is*  
14 *Disease?* Humana Press, p 1–134
- 15 Boorse C (2002) A rebuttal on functions. In: Ariew A, Cummins RC, Perlman M  
16 (eds) *Functions: New Essays in the Philosophy of Psychology and Biology*. Oxford  
17 University Press, p 63–112
- 18 Boorse C (2014) A second rebuttal on health. *Journal of Medicine and Philosophy*  
19 39(6):683–724. <https://doi.org/10.1093/jmp/jhu035>
- 20 Bouchard F (2013) How ecosystem evolution strengthens the case for functional plu-  
21 ralism. In: Huneman P (ed) *Functions: Selection and Mechanisms*. Springer, p  
22 83–95
- 23 Bozic I, Wu CJ (2020) Delineating the evolutionary dynamics of cancer  
24 from theory to reality. *Nature Cancer* 1(6):580–588. [https://doi.org/10.1038/](https://doi.org/10.1038/s43018-020-0079-6)  
25 [s43018-020-0079-6](https://doi.org/10.1038/s43018-020-0079-6)
- 26 Brandon RN (2013) *A General Case for Functional Pluralism*, Springer Netherlands,  
27 Dordrecht, pp 97–104. [https://doi.org/10.1007/978-94-007-5304-4\\_6](https://doi.org/10.1007/978-94-007-5304-4_6)
- 28 Buller DJ (1998) Etiological theories of function: A geographical survey. *Biology*  
29 *and Philosophy* 13(4):505–527. <https://doi.org/10.1023/A:1006559512367>
- 30 Bång-Rudenstam A, Cerezo-Magaña M, Belting M (2019) Pro-metastatic func-  
31 tions of lipoproteins and extracellular vesicles in the acidic tumor microen-  
32 vironment. *Cancer Metastasis Rev* 38(1-2):79–92. [https://doi.org/10.1007/](https://doi.org/10.1007/s10555-019-09786-5)  
33 [s10555-019-09786-5](https://doi.org/10.1007/s10555-019-09786-5)
- 34 Chiang YT, Chien YC, Lin YH, et al (2021) The function of the mutant p53-r175h in  
35 cancer. *Cancers* 13(16). <https://doi.org/https://doi.org/10.3390/cancers13164088>

- 1 Cummins R (1975) Functional analysis. *Journal of Philosophy* 72(November):741–  
2 64. <https://doi.org/10.2307/2024640>
- 3 Dussault AC, Bouchard F (2017) A persistence enhancing propensity account of eco-  
4 logical function to explain ecosystem evolution. *Synthese* 194(4). [https://doi.org/](https://doi.org/10.1007/s11229-016-1065-5)  
5 [10.1007/s11229-016-1065-5](https://doi.org/10.1007/s11229-016-1065-5)
- 6 Elgin CZ (2017) *True Enough*. Cambridge: MIT Press
- 7 Garson J (2011) Selected effects and causal role functions in the brain: The case for  
8 an etiological approach to neuroscience. *Biology and Philosophy* 26(4):547–565.  
9 <https://doi.org/10.1007/s10539-011-9262-6>
- 10 Garson J (2012) Function, selection, and construction in the brain. *Synthese*  
11 189(3):451–481. <https://doi.org/10.1007/s11229-012-0122-y>
- 12 Garson J (2013) The functional sense of mechanism. *Philosophy of Science*  
13 80(3):317–333. <https://doi.org/10.1086/671173>
- 14 Garson J (2016) *A Critical Overview of Biological Functions*. Dordrecht: Springer
- 15 Garson J (2017a) Against organizational functions. *Philosophy of Science*  
16 84(5):1093–1103. <https://doi.org/10.1086/694009>
- 17 Garson J (2017b) A generalized selected effects theory of function. *Philosophy of*  
18 *Science* 84(3):523–543. <https://doi.org/10.1086/692146>
- 19 Garson J (2018) How to be a function pluralist. *British Journal for the Philosophy of*  
20 *Science* 69(4):1101–1122. <https://doi.org/10.1093/bjps/axx007>
- 21 Gerlach K, Weigmann B (2019) The dichotomous function of interleukin-9 in  
22 cancer diseases. *J Mol Med (Berl)* 97(10):1377–1383. [https://doi.org/10.1007/](https://doi.org/10.1007/s00109-019-01826-5)  
23 [s00109-019-01826-5](https://doi.org/10.1007/s00109-019-01826-5)
- 24 Germain P (2012) Cancer cells and adaptive explanations. *Biology and Philosophy*  
25 27(6):785–810. <https://doi.org/10.1007/s10539-012-9334-2>
- 26 Germain P, Laplane L (2017) Metastasis as supra-cellular selection? a reply to lean  
27 and plutynski. *Biology and Philosophy* 32(2):281–287. [https://doi.org/10.1007/](https://doi.org/10.1007/s10539-016-9555-x)  
28 [s10539-016-9555-x](https://doi.org/10.1007/s10539-016-9555-x)
- 29 Giere RN (1999) Using models to represent reality. In: Magnani L, Nersessian NJ,  
30 Thagard P (eds) *Model-Based Reasoning in Scientific Discovery*. Kluwer/Plenum,  
31 p 41–57
- 32 Giere RN (2004) How models are used to represent reality. *Philosophy of Science*  
33 71(5):742–752. <https://doi.org/10.1086/425063>

- 1 Godfrey-Smith P (1993) Functions: Consensus without unity. *Pacific Philosophical*  
2 *Quarterly* 74(3):196–208. [https://doi.org/https://doi.org/10.1111/j.1468-0114.](https://doi.org/https://doi.org/10.1111/j.1468-0114.1993.tb00358.x)  
3 [1993.tb00358.x](https://doi.org/https://doi.org/10.1111/j.1468-0114.1993.tb00358.x)
- 4 Godfrey-Smith P (2006) The strategy of model-based science. *Biology and Philoso-*  
5 *phy* 21(5):725–740. <https://doi.org/10.1007/s10539-006-9054-6>
- 6 Godfrey-Smith P (2009a) *Darwinian Populations and Natural Selection*. Oxford  
7 University Press
- 8 Godfrey-Smith P (2009b) Models and fictions in science. *Philosophical Studies*  
9 143(1):101–116. <https://doi.org/10.1007/s11098-008-9313-2>
- 10 Goel HL, Mercurio AM (2013) Vegf targets the tumour cell. *Nat Rev Cancer*  
11 13(12):871–82. <https://doi.org/10.1038/nrc3627>
- 12 Goldwasser S (forthcoming) Finding normality in abnormality: On the ascription of  
13 normal functions to cancer. *Philosophy of Science* pp 1–11
- 14 Gonzalez LL, Garrie K, Turner MD (2020) Role of s100 proteins in health  
15 and disease. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*  
16 1867(6):118,677. <https://doi.org/https://doi.org/10.1016/j.bbamcr.2020.118677>
- 17 Greaves M, Maley CC (2012) Clonal evolution in cancer. *Nature* 481(7381):306–313.  
18 <https://doi.org/10.1038/nature10762>
- 19 Griffiths PE (1994) Cladistic classification and functional explanation. *Philosophy of*  
20 *Science* 61(2):206–227. <https://doi.org/10.1086/289796>
- 21 Griffiths PE (2006) Function, homology and character individuation. *Philosophy of*  
22 *Science* 73(1):1–25. <https://doi.org/10.1086/510172>
- 23 Halpern JY, Pearl J (2005) Causes and explanations: A structural-model approach.  
24 part i: Causes. *British Journal for the Philosophy of Science* 56(4):843–887. <https://doi.org/10.1093/bjps/axi147>  
25
- 26 Hardcastle VG (2002) On the normativity of functions. In: Ariew A, Cummins R,  
27 Perlman M (eds) *Functions: New Essays in the Philosophy of Psychology and*  
28 *Biology*. Clarendon Press, p 143–154
- 29 van Hateren JH (2017) A unifying theory of biological function. *Biological Theory*  
30 12(2):112–126. <https://doi.org/10.1007/s13752-017-0261-y>
- 31 Hausman DM (2012) Health, naturalism, and functional efficiency. *Philosophy of*  
32 *Science* 79(4):519–541. <https://doi.org/10.1086/668005>
- 33 Hausser J, Alon U (2020) Tumour heterogeneity and the evolutionary trade-  
34 offs of cancer. *Nature Reviews Cancer* 20(4):247–257. <https://doi.org/10.1038/>

1 s41568-020-0241-6

2 Ilhan M, Kucukkose C, Efe E, et al (2020) Pro-metastatic functions of notch signaling  
3 is mediated by *cyr61* in breast cells. *Eur J Cell Biol* 99(2-3):151,070. [https://doi.  
4 org/10.1016/j.ejcb.2020.151070](https://doi.org/10.1016/j.ejcb.2020.151070)

5 Joseph YH, Judea P (2005) Causes and explanations: A structural-model approach.  
6 part ii: Explanations. *British Journal for the Philosophy of Science* 56(4):889–911.  
7 <https://doi.org/10.1093/bjps/axi148>

8 Keeling DM, Garza P, Nartey CM, et al (2019) The meanings of 'function' in biology  
9 and the problematic case of *de novo* gene emergence. *eLife* 8:e47,014. [https://doi.  
10 org/10.7554/eLife.47014](https://doi.org/10.7554/eLife.47014)

11 Kitcher P (1993) Function and design. *Midwest Studies in Philosophy* 18(1):379–  
12 397. <https://doi.org/10.1111/j.1475-4975.1993.tb00274.x>

13 Laubichler MD, Stadler PF, Prohaska SJ, et al (2015) The relativity of biolog-  
14 ical function. *Theory in Biosciences* 134(3):143–147. [https://doi.org/10.1007/  
15 s12064-015-0215-5](https://doi.org/10.1007/s12064-015-0215-5), URL <https://doi.org/10.1007/s12064-015-0215-5>

16 Lean C, Plutynski A (2016) The evolution of failure: Explaining cancer as an evo-  
17 lutionary process. *Biology and Philosophy* 31(1):39–57. [https://doi.org/10.1007/  
18 s10539-015-9511-1](https://doi.org/10.1007/s10539-015-9511-1)

19 Lennox JG (2010) *La fonction biologique : phylogénie d'un concept*, Presses Uni-  
20 versitaires de France, Paris cedex 14, pp 17–42. [https://doi.org/10.3917/puf.gayon.  
21 2010.01.0017](https://doi.org/10.3917/puf.gayon.2010.01.0017)

22 Levy A (2015) Modeling without models. *Philosophical Studies* 172(3):781–798.  
23 <https://doi.org/10.1007/s11098-014-0333-9>

24 Lewontin RC (1970) The units of selection. *Annual Review of Ecology and System-  
25 atics* 1:1–18. URL <http://www.jstor.org/stable/2096764>

26 Loew C (2019) Causes as difference-makers for processes. *Philosophy and Phe-  
27 nomenological Research* 98(1):89–106. <https://doi.org/10.1111/phpr.12424>

28 Mashouri L, Yousefi H, Aref AR, et al (2019) Exosomes: composition, biogene-  
29 sis, and mechanisms in cancer metastasis and drug resistance. *Molecular Cancer*  
30 18(1):75. <https://doi.org/10.1186/s12943-019-0991-5>

31 Matsumoto K, Umitsu M, De Silva DM, et al (2017) Hepatocyte growth factor/met  
32 in cancer progression and biomarker discovery. *Cancer Science* 108(3):296–307.  
33 <https://doi.org/https://doi.org/10.1111/cas.13156>

34 Matthewson J, Griffiths PE (2017) Biological criteria of disease: Four ways of going  
35 wrong. *Journal of Medicine and Philosophy* 1(4). <https://doi.org/10.1093/jmp/>

1     jhx004

2     Mayr E (1961) Cause and effect in biology. *Science* 134(3489):1501–1506. <https://doi.org/doi:10.1126/science.134.3489.1501>

4     McLaughlin P (2000) *What Functions Explain: Functional Explanation and Self-Reproducing Systems*. Cambridge University Press

6     Millikan RG (1984) *Language, Thought, and Other Biological Categories: New Foundations for Realism*. MIT Press

8     Millikan RG (1989) In defense of proper functions. *Philosophy of Science* 56(June):288–302. <https://doi.org/10.1086/289488>

10    Millikan RG (1999) Wings, spoons, pills, and quills: A pluralist theory of function. *Journal of Philosophy* 96(4):191–206. <https://doi.org/jphil199996428>

12    Millikan RG (2002) Biofunctions: Two paradigms. In: Ariew A, Cummins R, Perlman M (eds) *Functions: New Essays in the Philosophy of Psychology and Biology*. Clarendon Press, p 113–143

15    Montévil M, Mossio M (2015) Biological organisation as closure of constraints. *Journal of Theoretical Biology* 372:179–191. <https://doi.org/https://doi.org/10.1016/j.jtbi.2015.02.029>

18    Morrow KH (forthcoming) A scale problem with the ecosystem services argument for protecting biodiversity. *Environmental Values* <https://doi.org/10.3197/096327122x16569260361751>

21    Mossio M, Saborido C, Moreno A (2009) An organizational account of biological functions. *British Journal for the Philosophy of Science* 60(4):813–841. <https://doi.org/10.1093/bjps/axp036>

24    Nanay B (2010) A modal theory of function. *Journal of Philosophy* 107(8):412–431. <https://doi.org/10.5840/jphil2010107834>

26    Neander K (1991a) Functions as selected effects: The conceptual analyst’s defense. *Philosophy of Science* 58(2):168–184. <https://doi.org/10.1086/289610>

28    Neander K (1991b) The teleological notion of ‘function’. *Australasian Journal of Philosophy* 69(4):454–468. <https://doi.org/10.1080/00048409112344881>

30    Neander K (2002) Types of traits: The importance of functional homologues. In: Ariew A, Cummins RC, Perlman M (eds) *Functions: New Essays in the Philosophy of Psychology and Biology*. Oxford University Press, p 390

33    Neander K (2017a) Functional analysis and the species design. *Synthese* 194(4). <https://doi.org/10.1007/s11229-015-0940-9>

- 1 Neander K (2017b) *A Mark of the Mental: A Defence of Informational Teleoseman-*  
2 *tics*. Cambridge, USA: MIT Press
- 3 Neander K, Rosenberg A (2012) Solving the circularity problem for functions: A  
4 response to nanay. *Journal of Philosophy* 109(10):613–622. [https://doi.org/10.](https://doi.org/10.5840/jphil20121091030)  
5 [5840/jphil20121091030](https://doi.org/10.5840/jphil20121091030)
- 6 Nunes-Neto N, Moreno A, El-Hani CN (2014) Function in ecology: An organiza-  
7 tional approach. *Biology and Philosophy* 29(1):123–141. [https://doi.org/10.1007/](https://doi.org/10.1007/s10539-013-9398-7)  
8 [s10539-013-9398-7](https://doi.org/10.1007/s10539-013-9398-7)
- 9 Okasha S (2021) Cancer and the levels of selection. *The British Journal for the*  
10 *Philosophy of Science* <https://doi.org/10.1086/716178>
- 11 Organ SL, Tsao MS (2011) An overview of the c-met signaling pathway. *Ther-*  
12 *apeutic Advances in Medical Oncology* 3(1):S7–S19. [https://doi.org/10.1177/](https://doi.org/10.1177/1758834011422556)  
13 [1758834011422556](https://doi.org/10.1177/1758834011422556)
- 14 Peinado H, Alečković M, Lavotshkin S, et al (2012) Melanoma exosomes educate  
15 bone marrow progenitor cells toward a pro-metastatic phenotype through met. *Nat*  
16 *Med* 18(6):883–91. <https://doi.org/10.1038/nm.2753>
- 17 Peng T, Wang G, Cheng S, et al (2020) The role and function of ppar $\gamma$  in bladder  
18 cancer. *Journal of Cancer* 11(13):3965–3975. <https://doi.org/10.7150/jca.42663>
- 19 Plutynski A (2017) Evolutionary perspectives on molecular medicine: Cancer from  
20 an evolutionary perspective. In: Boniolo G, Nathan MJ (eds) *Philosophy of*  
21 *Molecular Medicine: Foundational Issues in Research and Practice*. Routledge, p  
22 122–144
- 23 Plutynski A (2018) *Explaining Cancer: Finding Order in Disorder*. New York, NY,  
24 USA: Oxford University Press
- 25 Plutynski A (2019) Cancer modeling: The advantages and limitations of multiple per-  
26 spectives. In: Massimi M, McCoy C (eds) *Understanding Perspectivism: Scientific*  
27 *Challenges and Methodological Prospects*. New York: Routledge, p 160–177
- 28 Potochnik A (2017) *Idealization and the Aims of Science*. Chicago: University of  
29 Chicago Press
- 30 Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and  
31 metastasis. *Nature Medicine* 19(11):1423–1437. <https://doi.org/10.1038/nm.3394>
- 32 Rosenberg A, Neander K (2009) Are homologies (selected effect or causal role) func-  
33 tion free? *Philosophy of Science* 76(3):307–334. <https://doi.org/10.1086/649807>
- 34 Roux E (2014) The concept of function in modern physiology. *The Journal of Phys-*  
35 *iology* 592(11):2245–2249. <https://doi.org/https://doi.org/10.1113/jphysiol.2014.>



1 272062

2 Saborido C, Moreno A, González-Moreno M, et al (2016) Organizational malfunc-  
3 tions and the notions of health and disease. In: Giroux É (ed) *Naturalism in*  
4 *the Philosophy of Health. History, Philosophy and Theory of the Life Sciences.*  
5 Springer, Cham, p 101–120

6 Sartorio C (2005) Causes as difference-makers. *Philosophical Studies* 123(1-2):71–  
7 96. <https://doi.org/10.1007/s11098-004-5217-y>

8 Schlosser G (1998) Self-re-production and functionality. *Synthese* 116(3):303–354.  
9 <https://doi.org/10.1023/A:1005073307193>

10 Setty Y, Cohen IR, Dor Y, et al (2008) Four-dimensional realistic modeling of  
11 pancreatic organogenesis. *Proceedings of the National Academy of Sciences*  
12 105(51):20,374–20,379. <https://doi.org/doi:10.1073/pnas.0808725105>

13 Steiner C (2009) Unity in the concept of function. *Conceptus* 38(94):91–106. <https://doi.org/doi:10.1515/cpt-2009-9408>

15 Thomson-Jones MR (2005) Idealization and abstraction: A framework. In: Thomson-  
16 Jones MR, Cartwright N (eds) *Idealization XII: Correcting the Model. Idealization*  
17 *and Abstraction in the Sciences.* Rodopi, p 173–218

18 Weber M (2017) How objective are biological functions? *Synthese* 194(12):4741–  
19 4755. <https://doi.org/10.1007/s11229-017-1483-z>

20 Weisberg M (2007) Who is a modeler? *British Journal for the Philosophy of Science*  
21 58(2):207–233. <https://doi.org/10.1093/bjps/axm011>

22 Woodward J (2003) *Making Things Happen: A Theory of Causal Explanation.*  
23 Oxford University Press

24 Woodward J (2010) Causation in biology: Stability, specificity, and the choice of  
25 levels of explanation. *Biology and Philosophy* 25(3):287–318. <https://doi.org/10.1007/s10539-010-9200-z>

27 Wouters A (2005) The function debate in philosophy. *Acta Biotheoretica* 53(2):123–  
28 151. <https://doi.org/10.1007/s10441-005-5353-6>

29 Wright L (1973) Functions. *Philosophical Review* 82(2):139–168. <https://doi.org/10.2307/2183766>

31 Yu JH, Im CY, Min SH (2020) Function of pin1 in cancer development and its  
32 inhibitors as cancer therapeutics. *Frontiers in Cell and Developmental Biology* 8.  
33 <https://doi.org/10.3389/fcell.2020.00120>

- 1 Zebrowska A, Widlak PAO, Whiteside TAO, et al (2020) Signaling of tumor-derived  
2 sev impacts melanoma progression. *International Journal of Molecular Sciences*  
3 21(14):5066. <https://doi.org/https://doi.org/10.3390/ijms21145066>
- 4 Zhang L, Yu D (2019) Exosomes in cancer development, metastasis, and immunity.  
5 *Biochim Biophys Acta Rev Cancer* 1871(2):455–468. [https://doi.org/10.1016/j.](https://doi.org/10.1016/j.bbcan.2019.04.004)  
6 [bbcan.2019.04.004](https://doi.org/10.1016/j.bbcan.2019.04.004)